1
|
Speers AB, Wright KM, Brandes MS, Kedjejian N, Matthews DG, Caruso M, Harris CJ, Koike S, Nguyen T, Quinn JF, Soumyanath A, Gray NE. Mode of administration influences plasma levels of active Centella asiatica compounds in 5xFAD mice while markers of neuroinflammation remain unaltered. Front Neurosci 2024; 18:1277626. [PMID: 38591068 PMCID: PMC10999680 DOI: 10.3389/fnins.2024.1277626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2023] [Accepted: 03/13/2024] [Indexed: 04/10/2024] Open
Abstract
Introduction A water extract of Centella asiatica (L.) Urban [Apiaceae] (CAW) has demonstrated cognitive-enhancing effects in mouse models of Alzheimer's disease and aging, the magnitude of which is influenced by whether CAW is delivered in the drinking water or the diet. These cognitive benefits are accompanied by improvements in oxidative stress and mitochondrial function in the brain, two pathways related to the neuroinflammatory response. The effect of CAW on neuroinflammation, however, has not been directly studied. Here, we investigated the effect of CAW on neuroinflammation in 5xFAD mice and compared plasma levels of CAW's active compounds following two modes of CAW administration. Methods Eight-to-nine-month-old male and female 5xFAD mice and their wild-type littermates were administered CAW in their diet or drinking water (0 or 1,000 mg/kg/day) for five weeks. Immunohistochemistry was performed for β-amyloid (Aβ), glial fibrillary acidic protein (GFAP), and Griffonia simplicifolia lectin I (GSL I) in the cortex and hippocampus. Gene expression of inflammatory mediators (IL-6, TNFα, IL-1β, TREM2, AIF1, CX3CR1, CX3CL1, CD36, C3AR1, RAGE, CCR6, CD3E) was measured in the deep grey matter. Results CAW decreased cortical Aβ plaque burden in female 5xFAD mice administered CAW in the drinking water but had no effect on Aβ plaques in other treatment groups. CAW did not impact elevated levels of GFAP or GSL I in 5xFAD mice, regardless of sex, brain region, or mode of CAW administration. In the deep grey matter, CAW increased C3AR1 expression in 5xFAD females administered CAW in the drinking water and decreased IL-1β expression in 5xFAD males administered CAW in the diet. CAW had no effect, however, on gene expression levels of any other inflammatory mediator in the deep grey, for either sex or mode of CAW administration. Mice administered CAW in the drinking water versus the diet had significantly higher plasma levels of CAW compounds. Discussion CAW had little impact on the neuroinflammatory markers selected for evaluation in the present study, suggesting that the cognitive benefits of CAW may not be mediated by an anti-inflammatory effect or that additional molecular markers are needed to fully characterize the effect of CAW on neuroinflammation.
Collapse
Affiliation(s)
- Alex B. Speers
- BENFRA Botanical Dietary Supplements Research Center, Oregon Health & Science University, Portland, OR, United States
- Department of Neurology, Oregon Health & Science University, Portland, OR, United States
| | - Kirsten M. Wright
- BENFRA Botanical Dietary Supplements Research Center, Oregon Health & Science University, Portland, OR, United States
- Department of Neurology, Oregon Health & Science University, Portland, OR, United States
| | - Mikah S. Brandes
- BENFRA Botanical Dietary Supplements Research Center, Oregon Health & Science University, Portland, OR, United States
- Department of Neurology, Oregon Health & Science University, Portland, OR, United States
| | - Nareg Kedjejian
- BENFRA Botanical Dietary Supplements Research Center, Oregon Health & Science University, Portland, OR, United States
- Department of Neurology, Oregon Health & Science University, Portland, OR, United States
| | - Donald G. Matthews
- Department of Neurology, Oregon Health & Science University, Portland, OR, United States
| | - Maya Caruso
- Department of Neurology, Oregon Health & Science University, Portland, OR, United States
| | - Christopher J. Harris
- Department of Neurology, Oregon Health & Science University, Portland, OR, United States
| | - Seiji Koike
- BENFRA Botanical Dietary Supplements Research Center, Oregon Health & Science University, Portland, OR, United States
- School of Public Health, Oregon Health & Science University-Portland State University, Portland, OR, United States
| | - Thuan Nguyen
- BENFRA Botanical Dietary Supplements Research Center, Oregon Health & Science University, Portland, OR, United States
- School of Public Health, Oregon Health & Science University-Portland State University, Portland, OR, United States
| | - Joseph F. Quinn
- BENFRA Botanical Dietary Supplements Research Center, Oregon Health & Science University, Portland, OR, United States
- Department of Neurology, Oregon Health & Science University, Portland, OR, United States
- Parkinson’s Disease Research Education and Clinical Care Center, Veterans’ Administration Portland Health Care System, Portland, OR, United States
| | - Amala Soumyanath
- BENFRA Botanical Dietary Supplements Research Center, Oregon Health & Science University, Portland, OR, United States
- Department of Neurology, Oregon Health & Science University, Portland, OR, United States
| | - Nora E. Gray
- BENFRA Botanical Dietary Supplements Research Center, Oregon Health & Science University, Portland, OR, United States
- Department of Neurology, Oregon Health & Science University, Portland, OR, United States
| |
Collapse
|
2
|
Alcázar Magaña A, Vaswani A, Brown KS, Jiang Y, Alam MN, Caruso M, Lak P, Cheong P, Gray NE, Quinn JF, Soumyanath A, Stevens JF, Maier CS. Integrating High-Resolution Mass Spectral Data, Bioassays and Computational Models to Annotate Bioactives in Botanical Extracts: Case Study Analysis of C. asiatica Extract Associates Dicaffeoylquinic Acids with Protection against Amyloid-β Toxicity. Molecules 2024; 29:838. [PMID: 38398590 PMCID: PMC10892090 DOI: 10.3390/molecules29040838] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2023] [Revised: 02/07/2024] [Accepted: 02/12/2024] [Indexed: 02/25/2024] Open
Abstract
Rapid screening of botanical extracts for the discovery of bioactive natural products was performed using a fractionation approach in conjunction with flow-injection high-resolution mass spectrometry for obtaining chemical fingerprints of each fraction, enabling the correlation of the relative abundance of molecular features (representing individual phytochemicals) with the read-outs of bioassays. We applied this strategy for discovering and identifying constituents of Centella asiatica (C. asiatica) that protect against Aβ cytotoxicity in vitro. C. asiatica has been associated with improving mental health and cognitive function, with potential use in Alzheimer's disease. Human neuroblastoma MC65 cells were exposed to subfractions of an aqueous extract of C. asiatica to evaluate the protective benefit derived from these subfractions against amyloid β-cytotoxicity. The % viability score of the cells exposed to each subfraction was used in conjunction with the intensity of the molecular features in two computational models, namely Elastic Net and selectivity ratio, to determine the relationship of the peak intensity of molecular features with % viability. Finally, the correlation of mass spectral features with MC65 protection and their abundance in different sub-fractions were visualized using GNPS molecular networking. Both computational methods unequivocally identified dicaffeoylquinic acids as providing strong protection against Aβ-toxicity in MC65 cells, in agreement with the protective effects observed for these compounds in previous preclinical model studies.
Collapse
Affiliation(s)
- Armando Alcázar Magaña
- Department of Chemistry, Oregon State University, Corvallis, OR 97331, USA; (A.A.M.); (A.V.); (M.N.A.); (P.L.); (P.C.)
- BENFRA Botanical Dietary Supplements Research Center, Oregon Health & Science University, Portland, OR 97239, USA; (N.E.G.); (A.S.); (J.F.S.)
- Life Sciences Institute, University of British Columbia, Vancouver, BC V6T 1Z4, Canada
| | - Ashish Vaswani
- Department of Chemistry, Oregon State University, Corvallis, OR 97331, USA; (A.A.M.); (A.V.); (M.N.A.); (P.L.); (P.C.)
| | - Kevin S. Brown
- Department of Pharmaceutical Sciences, Oregon State University, Corvallis, OR 97331, USA;
- School of Chemical, Biological, and Environmental Engineering, Oregon State University, 116 Johnson Hall, 105 SW 26th Street, Corvallis, OR 97331, USA
| | - Yuan Jiang
- Department of Statistics, Oregon State University, Corvallis, OR 97331, USA;
| | - Md Nure Alam
- Department of Chemistry, Oregon State University, Corvallis, OR 97331, USA; (A.A.M.); (A.V.); (M.N.A.); (P.L.); (P.C.)
| | - Maya Caruso
- Department of Neurology, Oregon Health & Science University, Portland, OR 97239, USA; (M.C.); (J.F.Q.)
| | - Parnian Lak
- Department of Chemistry, Oregon State University, Corvallis, OR 97331, USA; (A.A.M.); (A.V.); (M.N.A.); (P.L.); (P.C.)
| | - Paul Cheong
- Department of Chemistry, Oregon State University, Corvallis, OR 97331, USA; (A.A.M.); (A.V.); (M.N.A.); (P.L.); (P.C.)
| | - Nora E. Gray
- BENFRA Botanical Dietary Supplements Research Center, Oregon Health & Science University, Portland, OR 97239, USA; (N.E.G.); (A.S.); (J.F.S.)
- Department of Neurology, Oregon Health & Science University, Portland, OR 97239, USA; (M.C.); (J.F.Q.)
| | - Joseph F. Quinn
- Department of Neurology, Oregon Health & Science University, Portland, OR 97239, USA; (M.C.); (J.F.Q.)
- Parkinson’s Disease Research Education and Clinical Care Center, Veterans’ Administration Portland Health Care System, Portland, OR 97239, USA
| | - Amala Soumyanath
- BENFRA Botanical Dietary Supplements Research Center, Oregon Health & Science University, Portland, OR 97239, USA; (N.E.G.); (A.S.); (J.F.S.)
- Department of Neurology, Oregon Health & Science University, Portland, OR 97239, USA; (M.C.); (J.F.Q.)
| | - Jan F. Stevens
- BENFRA Botanical Dietary Supplements Research Center, Oregon Health & Science University, Portland, OR 97239, USA; (N.E.G.); (A.S.); (J.F.S.)
- Department of Pharmaceutical Sciences, Oregon State University, Corvallis, OR 97331, USA;
- Linus Pauling Institute, Oregon State University, Corvallis, OR 97331, USA
| | - Claudia S. Maier
- Department of Chemistry, Oregon State University, Corvallis, OR 97331, USA; (A.A.M.); (A.V.); (M.N.A.); (P.L.); (P.C.)
- BENFRA Botanical Dietary Supplements Research Center, Oregon Health & Science University, Portland, OR 97239, USA; (N.E.G.); (A.S.); (J.F.S.)
- Linus Pauling Institute, Oregon State University, Corvallis, OR 97331, USA
| |
Collapse
|
3
|
Cannarella R, Caruso M, Condorelli RA, Timpanaro TA, Caruso MA, La Vignera S, Calogero AE. Testicular volume in 268 children and adolescents followed-up for childhood obesity-a retrospective cross-sectional study. Eur J Endocrinol 2023; 188:331-342. [PMID: 37127298 DOI: 10.1093/ejendo/lvad033] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/10/2022] [Revised: 12/21/2022] [Accepted: 03/06/2023] [Indexed: 05/03/2023]
Abstract
CONTEXT Prevalence of obesity in childhood has increased over the past few decades. The impact of obesity and of obesity-related metabolic disorders on testicular growth is unknown. OBJECTIVE To evaluate the impact of obesity, hyperinsulinemia, and insulin resistance on testicular volume (TV) in pre-pubertal (<9 years), peri-pubertal (9-14 years), and post-pubertal (14-16 years) periods. METHODS We collected data on TV, age, standard deviation score (SDS) of the body mass index (BMI), insulin, and fasting glycemia in 268 children and adolescents followed-up for weight control. RESULTS Peri-pubertal boys with normal weight had a significantly higher TV compared to those with overweight or obesity. No difference was found in the other age ranges when data were grouped according to BMI. Pre- and post-pubertal children/adolescents with normal insulin levels had significantly higher TV compared to those with hyperinsulinemia. Peri-pubertal boys with hyperinsulinemia had significantly higher TV compared to those with normal insulin levels. Post-pubertal adolescents with insulin resistance had lower TV and peri-pubertal boys had higher TV compared to those without insulin resistance. No difference was found in pre-puberty. CONCLUSIONS Closer control of the body weight and the associated metabolic alterations in childhood and adolescence may maintain testicular function later in life.
Collapse
Affiliation(s)
- R Cannarella
- Department of Clinical and Experimental Medicine, University of Catania, Catania 95123, Italy
| | - M Caruso
- Pediatric Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Catania 95123, Italy
| | - R A Condorelli
- Department of Clinical and Experimental Medicine, University of Catania, Catania 95123, Italy
| | - T A Timpanaro
- Pediatric Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Catania 95123, Italy
| | - M A Caruso
- Department of Clinical and Experimental Medicine, University of Catania, Catania 95123, Italy
| | - S La Vignera
- Department of Clinical and Experimental Medicine, University of Catania, Catania 95123, Italy
| | - A E Calogero
- Department of Clinical and Experimental Medicine, University of Catania, Catania 95123, Italy
| |
Collapse
|
4
|
Caruso M, Gastaldi L, Pastorelli S, Cereatti A, Digo E. An ISB-consistent Denavit-Hartenberg model of the human upper limb for joint kinematics optimization: validation on synthetic and robot data during a typical rehabilitation gesture. Annu Int Conf IEEE Eng Med Biol Soc 2022; 2022:1805-1808. [PMID: 36085675 DOI: 10.1109/embc48229.2022.9871201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Several biomedical contexts such as diagnosis, rehabilitation, and ergonomics require an accurate estimate of human upper limbs kinematics. Wearable inertial measurement units (IMU s) represent a suitable solution because of their unobtrusiveness, portability, and low-cost. However, the time-integration of the gyroscope angular velocity leads to an unbounded orientation drift affecting both angular and linear displacements over long observation interval. In this work, a Denavit-Hartenberg model of the upper limb was defined in accordance with the guidelines of the International Society of Biomechanics and exploited to design an optimization kinematics process. This procedure estimated the joint angles by minimizing the difference between the modelled and IMU-driven orientation of upper arm and forearm. In addition, reasonable constraints were added to limit the drift influence on the final joint kinematics accuracy. The validity of the procedure was tested on synthetic and experimental data acquired with a robotic arm over 20 minutes. Average rms errors amounted to 2.8 deg and 1.1 for synthetic and robot data, respectively. Clinical Relevance - The proposed method has the potential to improve robustness and accuracy of multi-joint kinematics estimation in the general contexts of home-based tele-rehabilitation interventions. In this respect adoption of multi-segmental kinematic model along with physiological joint constraints could contribute to address current limitations associated to unsupervised analysis in terms of monitoring and outcome assessment.
Collapse
|
5
|
Serretta V, Scalici Gesolfo C, Gebbia V, Borsellino N, Di Trapani D, Ferrera G, Spada M, Armenio A, Lamartina M, Valerio M, Di Grazia A, Pennisi M, Caruso M, Ruoppolo M, Barbera M, Adamo V, Cimino S, Firenze A, Piazza D, Macchiarella V, Fazio I, La Vecchia M. Virtual multi-institutional tumor board: Feasibility and physicians acceptance, a GSTU foundation project in Sicily. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00181-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
6
|
Wright KM, McFerrin J, Alcázar Magaña A, Roberts J, Caruso M, Kretzschmar D, Stevens JF, Maier CS, Quinn JF, Soumyanath A. Developing a Rational, Optimized Product of Centella asiatica for Examination in Clinical Trials: Real World Challenges. Front Nutr 2022; 8:799137. [PMID: 35096945 PMCID: PMC8797052 DOI: 10.3389/fnut.2021.799137] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2021] [Accepted: 12/21/2021] [Indexed: 11/13/2022] Open
Abstract
Botanical products are frequently sold as dietary supplements and their use by the public is increasing in popularity. However, scientific evaluation of their medicinal benefits presents unique challenges due to their chemical complexity, inherent variability, and the involvement of multiple active components and biological targets. Translation away from preclinical models, and developing an optimized, reproducible botanical product for use in clinical trials, presents particular challenges for phytotherapeutic agents compared to single chemical entities. Common deficiencies noted in clinical trials of botanical products include limited characterization of the product tested, inadequate placebo control, and lack of rationale for the type of product tested, dose used, outcome measures or even the study population. Our group has focused on the botanical Centella asiatica due to its reputation for enhancing cognition in Eastern traditional medicine systems. Our preclinical studies on a Centella asiatica water extract (CAW) and its bioactive components strongly support its potential as a phytotherapeutic agent for cognitive decline in aging and Alzheimer's disease through influences on antioxidant response, mitochondrial activity, and synaptic density. Here we describe our robust, scientific approach toward developing a rational phytotherapeutic product based on Centella asiatica for human investigation, addressing multiple factors to optimize its valid clinical evaluation. Specific aspects covered include approaches to identifying an optimal dose range for clinical assessment, design and composition of a dosage form and matching placebo, sourcing appropriate botanical raw material for product manufacture (including the evaluation of active compounds and contaminants), and up-scaling of laboratory extraction methods to available current Good Manufacturing Practice (cGMP) certified industrial facilities. We also address the process of obtaining regulatory approvals to proceed with clinical trials. Our study highlights the complexity of translational research on botanicals and the importance of identifying active compounds and developing sound analytical and bioanalytical methods for their determination in botanical materials and biological samples. Recent Phase I pharmacokinetic studies of our Centella asiatica product in humans (NCT03929250, NCT03937908) have highlighted additional challenges associated with designing botanical bioavailability studies, including specific dietary considerations that need to be considered.
Collapse
Affiliation(s)
- Kirsten M. Wright
- Department of Neurology, Oregon Health & Science University, Portland, OR, United States
| | | | - Armando Alcázar Magaña
- Department of Chemistry, Oregon State University, Corvallis, OR, United States
- Department of Pharmaceutical Sciences, Oregon State University, Corvallis, OR, United States
- Linus Pauling Institute, Oregon State University, Corvallis, OR, United States
| | | | - Maya Caruso
- Department of Neurology, Oregon Health & Science University, Portland, OR, United States
| | - Doris Kretzschmar
- Oregon Institute of Occupational Health Sciences, Oregon Health & Science University, Portland, OR, United States
| | - Jan F. Stevens
- Department of Pharmaceutical Sciences, Oregon State University, Corvallis, OR, United States
- Linus Pauling Institute, Oregon State University, Corvallis, OR, United States
| | - Claudia S. Maier
- Department of Chemistry, Oregon State University, Corvallis, OR, United States
- Linus Pauling Institute, Oregon State University, Corvallis, OR, United States
| | - Joseph F. Quinn
- Department of Neurology, Oregon Health & Science University, Portland, OR, United States
- Department of Neurology, Veterans Affairs Portland Health Care System Center, Portland, OR, United States
| | - Amala Soumyanath
- Department of Neurology, Oregon Health & Science University, Portland, OR, United States
| |
Collapse
|
7
|
Cabey K, Long DM, Law A, Gray NE, McClure C, Caruso M, Lak P, Wright KM, Stevens JF, Maier CS, Soumyanath A, Kretzschmar D. Withania somnifera and Centella asiatica Extracts Ameliorate Behavioral Deficits in an In Vivo Drosophila melanogaster Model of Oxidative Stress. Antioxidants (Basel) 2022; 11:antiox11010121. [PMID: 35052625 PMCID: PMC8773428 DOI: 10.3390/antiox11010121] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2021] [Revised: 12/28/2021] [Accepted: 12/31/2021] [Indexed: 02/05/2023] Open
Abstract
Due to an increase in the aging population, age-related diseases and age-related changes, such as diminished cognition and sleep disturbances, are an increasing health threat. It has been suggested that an increase in oxidative stress underlies many of these changes. Current treatments for these diseases and changes either have low efficacy or have deleterious side effects preventing long-time use. Therefore, alternative treatments that promote healthy aging and provide resilience against these health threats are needed. The herbs Withania somnifera and Centella asiatica may be two such alternatives because both have been connected with reducing oxidative stress and could therefore ameliorate age-related impairments. To test the effects of these herbs on behavioral phenotypes induced by oxidative stress, we used the Drosophila melanogaster sniffer mutant which has high levels of oxidative stress due to reduced carbonyl reductase activity. Effects on cognition and mobility were assessed using phototaxis assays and both, W. somnifera and C. asiatica water extracts improved phototaxis in sniffer mutants. In addition, W. somnifera improved nighttime sleep in male and female sniffer flies and promoted a less fragmented sleep pattern in male sniffer flies. This suggests that W. somnifera and C. asiatica can ameliorate oxidative stress-related changes in behavior and that by doing so they might promote healthy aging in humans.
Collapse
Affiliation(s)
- Kadine Cabey
- BENFRA Botanical Dietary Supplements Research Center, Oregon Health and Science University, Portland, OR 97239, USA; (K.C.); (D.M.L.); (A.L.); (N.E.G.); (C.M.); (K.M.W.); (A.S.)
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA;
- Helfgott Research Institute, National University of Natural Medicine, Portland, OR 97201, USA
| | - Dani M. Long
- BENFRA Botanical Dietary Supplements Research Center, Oregon Health and Science University, Portland, OR 97239, USA; (K.C.); (D.M.L.); (A.L.); (N.E.G.); (C.M.); (K.M.W.); (A.S.)
- Oregon Institute of Occupational Health Sciences, Oregon Health and Science University, Portland, OR 97239, USA
| | - Alexander Law
- BENFRA Botanical Dietary Supplements Research Center, Oregon Health and Science University, Portland, OR 97239, USA; (K.C.); (D.M.L.); (A.L.); (N.E.G.); (C.M.); (K.M.W.); (A.S.)
- Oregon Institute of Occupational Health Sciences, Oregon Health and Science University, Portland, OR 97239, USA
| | - Nora E. Gray
- BENFRA Botanical Dietary Supplements Research Center, Oregon Health and Science University, Portland, OR 97239, USA; (K.C.); (D.M.L.); (A.L.); (N.E.G.); (C.M.); (K.M.W.); (A.S.)
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA;
| | - Christine McClure
- BENFRA Botanical Dietary Supplements Research Center, Oregon Health and Science University, Portland, OR 97239, USA; (K.C.); (D.M.L.); (A.L.); (N.E.G.); (C.M.); (K.M.W.); (A.S.)
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA;
| | - Maya Caruso
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA;
| | - Parnian Lak
- Department of Chemistry, Oregon State University, Corvallis, OR 97331, USA; (P.L.); (C.S.M.)
- Linus Pauling Institute, Oregon State University, Corvallis, OR 97331, USA;
| | - Kirsten M. Wright
- BENFRA Botanical Dietary Supplements Research Center, Oregon Health and Science University, Portland, OR 97239, USA; (K.C.); (D.M.L.); (A.L.); (N.E.G.); (C.M.); (K.M.W.); (A.S.)
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA;
| | - Jan F. Stevens
- Linus Pauling Institute, Oregon State University, Corvallis, OR 97331, USA;
- College of Pharmacy, Oregon State University, Corvallis, OR 97331, USA
| | - Claudia S. Maier
- Department of Chemistry, Oregon State University, Corvallis, OR 97331, USA; (P.L.); (C.S.M.)
- Linus Pauling Institute, Oregon State University, Corvallis, OR 97331, USA;
| | - Amala Soumyanath
- BENFRA Botanical Dietary Supplements Research Center, Oregon Health and Science University, Portland, OR 97239, USA; (K.C.); (D.M.L.); (A.L.); (N.E.G.); (C.M.); (K.M.W.); (A.S.)
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA;
| | - Doris Kretzschmar
- BENFRA Botanical Dietary Supplements Research Center, Oregon Health and Science University, Portland, OR 97239, USA; (K.C.); (D.M.L.); (A.L.); (N.E.G.); (C.M.); (K.M.W.); (A.S.)
- Oregon Institute of Occupational Health Sciences, Oregon Health and Science University, Portland, OR 97239, USA
- Correspondence:
| |
Collapse
|
8
|
Speers AB, García-Jaramillo M, Feryn A, Matthews DG, Lichtenberg T, Caruso M, Wright KM, Quinn JF, Stevens JF, Maier CS, Soumyanath A, Gray NE. Centella asiatica Alters Metabolic Pathways Associated With Alzheimer's Disease in the 5xFAD Mouse Model of ß-Amyloid Accumulation. Front Pharmacol 2022; 12:788312. [PMID: 34975484 PMCID: PMC8717922 DOI: 10.3389/fphar.2021.788312] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2021] [Accepted: 11/30/2021] [Indexed: 11/13/2022] Open
Abstract
Centella asiatica is an herb used in Ayurvedic and traditional Chinese medicine for its beneficial effects on brain health and cognition. Our group has previously shown that a water extract of Centella asiatica (CAW) elicits cognitive-enhancing effects in animal models of aging and Alzheimer's disease, including a dose-related effect of CAW on memory in the 5xFAD mouse model of ß-amyloid accumulation. Here, we endeavor to elucidate the mechanisms underlying the effects of CAW in the brain by conducting a metabolomic analysis of cortical tissue from 5xFAD mice treated with increasing concentrations of CAW. Tissue was collected from 8-month-old male and female 5xFAD mice and their wild-type littermates treated with CAW (0, 200, 500, or 1,000 mg/kg/d) dissolved in their drinking water for 5 weeks. High-performance liquid chromatography coupled to high-resolution mass spectrometry analysis was performed and relative levels of 120 annotated metabolites were assessed in the treatment groups. Metabolomic analysis revealed sex differences in the effect of the 5xFAD genotype on metabolite levels compared to wild-type mice, and variations in the metabolomic response to CAW depending on sex, genotype, and CAW dose. In at least three of the four treated groups (5xFAD or wild-type, male or female), CAW (500 mg/kg/d) significantly altered metabolic pathways related to purine metabolism, nicotinate and nicotinamide metabolism, and glycerophospholipid metabolism. The results are in line with some of our previous findings regarding specific mechanisms of action of CAW (e.g., improving mitochondrial function, reducing oxidative stress, and increasing synaptic density). Furthermore, these findings provide new information about additional, potential mechanisms for the cognitive-enhancing effect of CAW, including upregulation of nicotinamide adenine dinucleotide in the brain and modulation of brain-derived neurotrophic factor. These metabolic pathways have been implicated in the pathophysiology of Alzheimer's disease, highlighting the therapeutic potential of CAW in this neurodegenerative disease.
Collapse
Affiliation(s)
- Alex B Speers
- Department of Neurology, Oregon Health & Science University, Portland, OR, United States
| | - Manuel García-Jaramillo
- Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, United States.,Linus Pauling Institute, Oregon State University, Corvallis, OR, United States.,Department of Chemistry, Oregon State University, Corvallis, OR, United States
| | - Alicia Feryn
- OHSU-PSU School of Public Health, Oregon Health & Science University, Portland, OR, United States
| | - Donald G Matthews
- Department of Neurology, Oregon Health & Science University, Portland, OR, United States
| | - Talia Lichtenberg
- Department of Neurology, Oregon Health & Science University, Portland, OR, United States
| | - Maya Caruso
- Department of Neurology, Oregon Health & Science University, Portland, OR, United States
| | - Kirsten M Wright
- Department of Neurology, Oregon Health & Science University, Portland, OR, United States
| | - Joseph F Quinn
- Department of Neurology, Oregon Health & Science University, Portland, OR, United States.,Parkinson's Disease Research Education and Clinical Care Center, Veterans' Administration Portland Health Care System, Portland, OR, United States
| | - Jan F Stevens
- Linus Pauling Institute, Oregon State University, Corvallis, OR, United States.,Department of Pharmaceutical Sciences, Oregon State University, Corvallis, OR, United States
| | - Claudia S Maier
- Linus Pauling Institute, Oregon State University, Corvallis, OR, United States.,Department of Chemistry, Oregon State University, Corvallis, OR, United States
| | - Amala Soumyanath
- Department of Neurology, Oregon Health & Science University, Portland, OR, United States
| | - Nora E Gray
- Department of Neurology, Oregon Health & Science University, Portland, OR, United States
| |
Collapse
|
9
|
Khorani M, Bobe G, Matthews DG, Magana AA, Caruso M, Gray NE, Quinn JF, Stevens JF, Soumyanath A, Maier CS. The Impact of the hAPP695SW Transgene and Associated Amyloid-β Accumulation on Murine Hippocampal Biochemical Pathways. J Alzheimers Dis 2021; 85:1601-1619. [DOI: 10.3233/jad-215084] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Background: Alzheimer’s disease (AD) is a neurodegenerative disease characterized by the accumulation of amyloid-β (Aβ) peptide in the brain. Objective: Gain a better insight into alterations in major biochemical pathways underlying AD. Methods: We compared metabolomic profiles of hippocampal tissue of 20-month-old female Tg2576 mice expressing the familial AD-associated hAPP695SW transgene with their 20-month-old wild type female littermates. Results: The hAPP695SW transgene causes overproduction and accumulation of Aβ in the brain. Out of 180 annotated metabolites, 54 metabolites differed (30 higher and 24 lower in Tg2576 versus wild-type hippocampal tissue) and were linked to the amino acid, nucleic acid, glycerophospholipid, ceramide, and fatty acid metabolism. Our results point to 1) heightened metabolic activity as indicated by higher levels of urea, enhanced fatty acid β-oxidation, and lower fatty acid levels; 2) enhanced redox regulation; and 3) an imbalance of neuro-excitatory and neuro-inhibitory metabolites in hippocampal tissue of aged hAPP695SW transgenic mice. Conclusion: Taken together, our results suggest that dysregulation of multiple metabolic pathways associated with a concomitant shift to an excitatory-inhibitory imbalance are contributing mechanisms of AD-related pathology in the Tg2576 mouse.
Collapse
Affiliation(s)
- Mona Khorani
- Department of Chemistry, Oregon State University, Corvallis, OR, USA
| | - Gerd Bobe
- Linus Pauling Institute, Oregon State University, Corvallis, OR, USA
| | - Donald G. Matthews
- Department of Neurology, Oregon Health & Science University, Portland, OR, USA
| | - Armando Alcazar Magana
- Department of Chemistry, Oregon State University, Corvallis, OR, USA
- Linus Pauling Institute, Oregon State University, Corvallis, OR, USA
| | - Maya Caruso
- Department of Neurology, Oregon Health & Science University, Portland, OR, USA
| | - Nora E. Gray
- Department of Neurology, Oregon Health & Science University, Portland, OR, USA
| | - Joseph F. Quinn
- Department of Neurology, Oregon Health & Science University, Portland, OR, USA
- Parkinson’s Disease Research Education and Clinical Care Center, Veterans’ Administration Portland Health Care System, Portland, OR, USA
| | - Jan F. Stevens
- Linus Pauling Institute, Oregon State University, Corvallis, OR, USA
- Department of Pharmaceutical Sciences, Oregon State University, Corvallis, OR, USA
| | - Amala Soumyanath
- Department of Neurology, Oregon Health & Science University, Portland, OR, USA
| | - Claudia S. Maier
- Department of Chemistry, Oregon State University, Corvallis, OR, USA
- Linus Pauling Institute, Oregon State University, Corvallis, OR, USA
| |
Collapse
|
10
|
Zuniga A, Smith ML, Caruso M, Ryabinin AE. Vesicular glutamate transporter 2-containing neurons of the centrally-projecting Edinger-Westphal nucleus regulate alcohol drinking and body temperature. Neuropharmacology 2021; 200:108795. [PMID: 34555367 DOI: 10.1016/j.neuropharm.2021.108795] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2020] [Revised: 08/28/2021] [Accepted: 09/14/2021] [Indexed: 12/19/2022]
Abstract
Previous studies in rodents have repeatedly demonstrated that the centrally-projecting Edinger-Westphal nucleus (EWcp) is highly sensitive to alcohol and is also involved in regulating alcohol intake and body temperature. Historically, the EWcp has been known as the main site of Urocortin 1 (Ucn1) expression, a corticotropin-releasing factor-related peptide, in the brain. However, the EWcp also contains other populations of neurons, including neurons that express the vesicular glutamate transporter 2 (Vglut2). Here we transduced the EWcp with adeno-associated viruses (AAVs) encoding Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) to test the role of the EWcp in alcohol drinking and in the regulation of body temperature. Activation of the EWcp with excitatory DREADDs inhibited alcohol intake in a 2-bottle choice procedure in male C57BL/6J mice, whereas inhibition of the EWcp with DREADDs had no effect. Surprisingly, analysis of DREADD expression indicated Ucn1-containing neurons of the EWcp did not express DREADDs. In contrast, AAVs transduced non-Ucn1-containing EWcp neurons. Subsequent experiments showed that the inhibitory effect of EWcp activation on alcohol intake was also present in male Ucn1 KO mice, suggesting that a Ucn1-devoid population of EWcp regulates alcohol intake. A final set of chemogenetic experiments showed that activation of Vglut2-expressing EWcp neurons inhibited alcohol intake and induced hypothermia in male and female mice. These studies expand on previous literature by indicating that a glutamatergic, Ucn1-devoid subpopulation of the EWcp regulates alcohol consumption and body temperature.
Collapse
Affiliation(s)
- Alfredo Zuniga
- Department of Behavioral Neuroscience, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA.
| | - Monique L Smith
- Department of Behavioral Neuroscience, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA
| | - Maya Caruso
- Department of Behavioral Neuroscience, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA
| | - Andrey E Ryabinin
- Department of Behavioral Neuroscience, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA
| |
Collapse
|
11
|
Salis F, Bertuletti S, Scott K, Caruso M, Bonci T, Buckley E, Croce UD, Mazza C, Cereatti A. A wearable multi-sensor system for real world gait analysis. Annu Int Conf IEEE Eng Med Biol Soc 2021; 2021:7020-7023. [PMID: 34892719 DOI: 10.1109/embc46164.2021.9630392] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Gait analysis is commonly performed in standardized environments, but there is a growing interest in assessing gait also in ecological conditions. In this regard, an important limitation is the lack of an accurate mobile gold standard for validating any wearable system, such as continuous monitoring devices mounted on the trunk or wrist. This study therefore deals with the development and validation of a new wearable multi-sensor-based system for digital gait assessment in free-living conditions. In particular, results obtained from five healthy subjects during lab-based and real-world experiments were presented and discussed. The in-lab validation, which assessed the accuracy and reliability of the proposed system, shows median percentage errors smaller than 2% in the estimation of spatio-temporal parameters. The system also proved to be easy to use, comfortable to wear and robust during the out-of-lab acquisitions, showing its feasibility for free-living applications.
Collapse
|
12
|
Polosa R, Emma R, Cibella F, Caruso M, Conte G, Benfatto F, Ferlito S, Gulino A, Malerba M, Caponnetto P. Impact of exclusive e-cigarettes and heated tobacco products use on muco-ciliary clearance. Ther Adv Chronic Dis 2021; 12:20406223211035267. [PMID: 34422253 PMCID: PMC8371723 DOI: 10.1177/20406223211035267] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2021] [Accepted: 07/07/2021] [Indexed: 11/29/2022] Open
Abstract
Background: Tobacco smoking impairs mucociliary clearance (MCC) efficiency as shown by
prolonged saccharin test transit time (STTT). Avoiding exposure to tobacco
smoke from combustible cigarettes may restore MCC function and former
smokers have been shown to exhibit similar STTT as never smokers. The impact
on STTT of switching from smoking to combustion-free tobacco products such
as e-cigarettes (ECs) and heated tobacco products (HTPs) is not known. Methods: We report STTT of exclusive EC and HTP users. Test results were compared with
those obtained in current, former, and never smokers. Results: STTT were obtained from 39 current, 40 former, 40 never smokers, and from 20
EC and 20 HTP users. Comparison of STTT values showed significant difference
among the five study groups (p < 0.00001) with current
smokers having a median [interquartile range (IQR)] STTT of 13.15 min, which
was significantly longer compared with that of all other study groups. In
particular, compared with former (7.26 min) and never smokers (7.24 min),
exclusive EC users and exclusive HTP users had similar STTT at 7.00 and
8.00 min, respectively. Conclusion: Former smokers who have switched to exclusive regular use of combustion-free
nicotine delivery systems (i.e., ECs and HTPs) exhibit similar saccharin
transit time as never and former smokers. This suggests that combustion-free
nicotine delivery technologies are unlikely to have detrimental effects on
MCC function.
Collapse
Affiliation(s)
- R Polosa
- Centre for the Prevention and Treatment of Tobacco Addiction (CPCT), Teaching Hospital Policlinico - V. Emanuele, University of Catania, Catania, Italy Center of Excellence for the Acceleration of Harm Reduction (CoEHAR), University of Catania, Italy Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy
| | - R Emma
- Centre for the Prevention and Treatment of Tobacco Addiction (CPCT), Teaching Hospital Policlinico - V. Emanuele, University of Catania, Catania, Italy, Center of Excellence for the Acceleration of Harm Reduction (CoEHAR), University of Catania, Catania, Italy
| | - F Cibella
- National Research Council of Italy, Institute of Biomedicine and Molecular Immunology, Palermo, Italy
| | - M Caruso
- Centre for the Prevention and Treatment of Tobacco Addiction (CPCT), Teaching Hospital Policlinico - V. Emanuele, University of Catania, Catania, Italy, Center of Excellence for the Acceleration of Harm Reduction (CoEHAR), University of Catania, Catania, Italy
| | - G Conte
- Centre for the Prevention and Treatment of Tobacco Addiction (CPCT), Teaching Hospital Policlinico - V. Emanuele, University of Catania, Catania, Italy
| | - F Benfatto
- Centre for the Prevention and Treatment of Tobacco Addiction (CPCT), Teaching Hospital Policlinico - V. Emanuele, University of Catania, Catania, Italy
| | - S Ferlito
- Department of Medical Science, Surgical Science and advanced Technologies G.F, Ingrassia, University of Catania, Catania, Italy
| | - A Gulino
- Department of Medical Science, Surgical Science and advanced Technologies G.F, Ingrassia, University of Catania, Catania, Italy
| | - M Malerba
- Translational Medicine Department, Eastern Piedmont University (UPO), Novara, Italy
| | - P Caponnetto
- Centre for the Prevention and Treatment of Tobacco Addiction (CPCT), Teaching Hospital Policlinico - V. Emanuele, University of Catania, Catania, Italy, Center of Excellence for the Acceleration of Harm Reduction (CoEHAR), University of Catania, Catania, Italy
| |
Collapse
|
13
|
Zweig JA, Brandes MS, Brumbach BH, Caruso M, Wright KM, Quinn JF, Soumyanath A, Gray NE. Loss of NRF2 accelerates cognitive decline, exacerbates mitochondrial dysfunction, and is required for the cognitive enhancing effects of Centella asiatica during aging. Neurobiol Aging 2021; 100:48-58. [PMID: 33486357 PMCID: PMC7920997 DOI: 10.1016/j.neurobiolaging.2020.11.019] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2019] [Revised: 11/30/2020] [Accepted: 11/30/2020] [Indexed: 02/07/2023]
Abstract
The water extract of Centella asiatica (CAW) improves cognitive and mitochondrial function and activates the nuclear factor erythroid 2-related factor 2 (NRF2) regulated antioxidant response pathway in aged mice. Here we investigate whether NRF2 activation is required for the cognitive and mitochondrial effects of prolonged CAW exposure during aging. Five-month-old NRF2 knockout (NRF2KO) and wild-type mice were treated with CAW for 1, 7, or 13 months. Each cohort underwent cognitive testing and hippocampal mitochondrial analyses. Age-related cognitive decline was accelerated in NRF2KO mice and while CAW treatment improved cognitive performance in wild-type mice, it had no effect on NRF2KO animals. Hippocampal mitochondrial function also declined further with age in NRF2KO mice and greater hippocampal mitochondrial dysfunction was associated with poorer cognitive performance in both genotypes. Long-term CAW treatment did not affect mitochondrial endpoints in animals of either genotype. These data indicate that loss of NRF2 results in accelerated age-related cognitive decline and worsened mitochondrial deficits. NRF2 also appears to be required for the cognitive enhancing effects of CAW during aging.
Collapse
Affiliation(s)
- Jonathan A Zweig
- Department of Neurology, Oregon Health & Science University, Portland, OR, USA
| | - Mikah S Brandes
- Department of Neurology, Oregon Health & Science University, Portland, OR, USA
| | - Barbara H Brumbach
- Biostatistics & Design Program, Oregon Health & Science University, Portland, OR, USA
| | - Maya Caruso
- Department of Neurology, Oregon Health & Science University, Portland, OR, USA
| | - Kirsten M Wright
- Department of Neurology, Oregon Health & Science University, Portland, OR, USA
| | - Joseph F Quinn
- Department of Neurology, Oregon Health & Science University, Portland, OR, USA; Department of Neurology and Parkinson's Disease Research Education and Clinical Care Center (PADRECC), VA Portland Healthcare System, Portland, OR, USA
| | - Amala Soumyanath
- Department of Neurology, Oregon Health & Science University, Portland, OR, USA
| | - Nora E Gray
- Department of Neurology, Oregon Health & Science University, Portland, OR, USA.
| |
Collapse
|
14
|
Zweig JA, Brandes MS, Brumbach BH, Caruso M, Wright KM, Quinn JF, Soumyanath A, Gray NE. Prolonged Treatment with Centella asiatica Improves Memory, Reduces Amyloid-β Pathology, and Activates NRF2-Regulated Antioxidant Response Pathway in 5xFAD Mice. J Alzheimers Dis 2021; 81:1453-1468. [PMID: 33935097 PMCID: PMC10878128 DOI: 10.3233/jad-210271] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
BACKGROUND The medicinal herb Centella asiatica has been long been used for its neuroprotective and cognitive enhancing effects. We have previously shown that two weeks of treatment with a water extract of Centella asiatica (CAW) improves cognition and activates the endogenous antioxidant response pathway without altering amyloid-β (Aβ) plaque burden. OBJECTIVE Here, we assess the effect of long-term treatment of CAW in the 5xFAD mouse model of Aβ accumulation. METHODS Four-month-old 5xFAD mice were treated with CAW in their drinking water (2 g/L) for three months at which point they underwent cognitive testing as well as analysis of Aβ plaque levels and antioxidant and synaptic gene expression. In order to confirm the involvement of the antioxidant regulatory transcription factor NRF2 on the effects of CAW on synaptic plasticity, neurons isolated from 5xFAD mice were also treated with CAW and the targeted inhibitor ML385. RESULTS Three months of treatment with CAW improved spatial and contextual memory as well as executive function in 5xFAD mice. This improvement was accompanied by increased antioxidant gene expression and a decrease in Aβ plaque burden relative to untreated 5xFAD animals. In isolated neurons, treatment with ML385 blocked the effects of CAW on dendritic arborization and synaptic gene expression. CONCLUSION These results suggest that prolonged CAW exposure could be beneficial in Alzheimer's disease and that these effects likely involve NRF2 activation. Moreover, these findings suggest that targeting NRF2 itself may be a relevant therapeutic strategy for improving synaptic plasticity and cognitive function in Alzheimer's disease.
Collapse
Affiliation(s)
- Jonathan A. Zweig
- Department of Neurology, Oregon Health & Science University, Portland, OR, USA
| | - Mikah S. Brandes
- Department of Neurology, Oregon Health & Science University, Portland, OR, USA
| | - Barbara H. Brumbach
- Biostatistics & Design Program Core, Oregon Health & Science University, Portland, OR, USA
| | - Maya Caruso
- Department of Neurology, Oregon Health & Science University, Portland, OR, USA
| | - Kirsten M. Wright
- Department of Neurology, Oregon Health & Science University, Portland, OR, USA
| | - Joseph F. Quinn
- Department of Neurology, Oregon Health & Science University, Portland, OR, USA
- Department of Neurology and Parkinson’s Disease Research Education and Clinical Care Center (PADRECC), VA Portland Healthcare System, Portland, OR, USA
| | - Amala Soumyanath
- Department of Neurology, Oregon Health & Science University, Portland, OR, USA
| | - Nora E. Gray
- Department of Neurology, Oregon Health & Science University, Portland, OR, USA
| |
Collapse
|
15
|
Wright KM, Magana AA, Bollen M, Caruso M, Gray NE, Matthews DG, David JC, Mepham B, Stevens JF, Maier CS, Quinn JF, Soumyanath A. From source to bedside: Translational studies of
centella asiatica
for Alzheimer's disease. Alzheimers Dement 2020. [DOI: 10.1002/alz.041268] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
| | | | - Melissa Bollen
- Oregon Health & Science University Portland OR USA
- National University of Natural Medicine Portland OR USA
| | - Maya Caruso
- Oregon Health & Science University Portland OR USA
| | - Nora E. Gray
- Oregon Health & Science University Portland OR USA
| | | | | | | | - Jan F. Stevens
- Oregon State University Corvallis OR USA
- Linus Pauling Institute Corvallis OR USA
| | | | | | | |
Collapse
|
16
|
Rizza S, Pietroiusti A, Farcomeni A, Mina GG, Caruso M, Virgilio M, Magrini A, Federici M, Coppeta L. Monthly fluctuations in 25-hydroxy-vitamin D levels in day and rotating night shift hospital workers. J Endocrinol Invest 2020; 43:1655-1660. [PMID: 32342444 DOI: 10.1007/s40618-020-01265-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/20/2020] [Accepted: 04/17/2020] [Indexed: 12/14/2022]
Abstract
PURPOSE Epidemiological studies have suggested that indoor hospital employees, either day or night shift workers, are at high risk of metabolic and cardiovascular diseases. Interestingly, previous reports have also described a higher prevalence of vitamin D (25OHD) deficiency among these workers. However, few studies have determined the monthly variations in 25OHD levels in indoor hospital employees. METHODS To address this lack of knowledge, in 2018, during the periodic health surveillance checks at the Service of Occupational Medicine, we measured 25OHD levels in a group of indoor hospital workers (88 rotating night shift workers vs 200 day workers). Each participant received a single annual health surveillance check. RESULTS The mean levels of 25OHD were consistently below the lower limit of the normal range in both groups throughout the year. Only in the summer, day workers but not rotating night shift workers (mean 25.9 ± 11.3 ng/ml vs 23.1 ± 9.1 ng/ml; p = 0.042) showed levels significantly higher than those in the other seasons. This difference remained statistically significant even after correction for study covariates [β = - 1.649 (CI - 0.283/- 3.482), p = 0.039]. A cosinor analysis confirmed that the difference in the 25OHD levels between groups was present later in the year. CONCLUSIONS We found that relatively young healthy hospital workers, especially those with rotating night shifts, in the absence of significant metabolic risk factors, have a high risk of 25OHD deficiency/insufficiency. Because 25OHD deficiency may lead to a progression to more severe conditions such as osteoporosis or bone fractures, our results should be verified in larger cohorts including different ancestries.
Collapse
Affiliation(s)
- S Rizza
- Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.
| | - A Pietroiusti
- Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy
| | - A Farcomeni
- Department of Economics and Finance, University of Rome Tor Vergata, Rome, Italy
| | - G G Mina
- Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy
| | - M Caruso
- Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy
| | - M Virgilio
- Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy
| | - A Magrini
- Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy
| | - M Federici
- Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy
| | - L Coppeta
- Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy
| |
Collapse
|
17
|
Alcazar Magana A, Wright K, Vaswani A, Caruso M, Reed RL, Bailey CF, Nguyen T, Gray NE, Soumyanath A, Quinn J, Stevens JF, Maier CS. Integration of mass spectral fingerprinting analysis with precursor ion (MS1) quantification for the characterisation of botanical extracts: application to extracts of Centella asiatica (L.) Urban. Phytochem Anal 2020; 31:722-738. [PMID: 32281154 PMCID: PMC7587007 DOI: 10.1002/pca.2936] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/04/2019] [Revised: 03/12/2020] [Accepted: 03/22/2020] [Indexed: 05/16/2023]
Abstract
INTRODUCTION The phytochemical composition of plant material governs the bioactivity and potential health benefits as well as the outcomes and reproducibility of laboratory studies and clinical trials. OBJECTIVE The objective of this work was to develop an efficient method for the in-depth characterisation of plant extracts and quantification of marker compounds that can be potentially used for subsequent product integrity studies. Centella asiatica (L.) Urb., an Ayurvedic herb with potential applications in enhancing mental health and cognitive function, was used as a case study. METHODS A quadrupole time-of-flight analyser in conjunction with an optimised high-performance liquid chromatography (HPLC) separation was used for in-depth untargeted fingerprinting and post-acquisition precursor ion quantification to determine levels of distinct phytochemicals in various C. asiatica extracts. RESULTS We demonstrate the utility of this workflow for the characterisation of extracts of C. asiatica. This integrated workflow allowed the identification or tentative identification of 117 compounds, chemically interconnected based on Tanimoto chemical similarity, and the accurate quantification of 24 phytochemicals commonly found in C. asiatica extracts. CONCLUSION We report a phytochemical analysis method combining liquid chromatography, high resolution mass spectral data acquisition, and post-acquisition interrogation that allows chemical fingerprints of botanicals to be obtained in conjunction with accurate quantification of distinct phytochemicals. The variability in the composition of specialised metabolites across different C. asiatica accessions was substantial, demonstrating that detailed characterisation of plant extracts is a prerequisite for reproducible use in laboratory studies, clinical trials and safe consumption. The methodological approach is generally applicable to other botanical products.
Collapse
Affiliation(s)
- Armando Alcazar Magana
- Department of ChemistryOregon State UniversityCorvallisORUSA
- Linus Pauling InstituteOregon State UniversityCorvallisORUSA
| | - Kirsten Wright
- Department of NeurologyOregon Health and Science UniversityPortlandORUSA
| | - Ashish Vaswani
- Department of ChemistryOregon State UniversityCorvallisORUSA
| | - Maya Caruso
- Department of NeurologyOregon Health and Science UniversityPortlandORUSA
| | - Ralph L. Reed
- Department of Pharmaceutical SciencesOregon State UniversityCorvallisORUSA
- Linus Pauling InstituteOregon State UniversityCorvallisORUSA
| | | | - Thuan Nguyen
- OHSU‐PSU School of Public Health, Oregon Health & Science UniversityPortlandORUSA
| | - Nora E. Gray
- Department of NeurologyOregon Health and Science UniversityPortlandORUSA
| | - Amala Soumyanath
- Department of NeurologyOregon Health and Science UniversityPortlandORUSA
| | - Joseph Quinn
- Department of NeurologyOregon Health and Science UniversityPortlandORUSA
- Department of Neurology and Parkinson's Disease Research Education and Clinical Care Center (PADRECC), VA Portland Healthcare SystemPortlandORUSA
| | - Jan F. Stevens
- Department of Pharmaceutical SciencesOregon State UniversityCorvallisORUSA
- Linus Pauling InstituteOregon State UniversityCorvallisORUSA
| | - Claudia S. Maier
- Department of ChemistryOregon State UniversityCorvallisORUSA
- Linus Pauling InstituteOregon State UniversityCorvallisORUSA
| |
Collapse
|
18
|
Abstract
Background:Environmental copper has been implicated in the pathogenesis of Alzheimer’s disease based on evidence that: 1) brain copper levels increase with age, 2) copper promotes misfolding and toxicity of amyloid-β in vitro, 3) copper-modulating interventions reduce amyloid pathology in animal models. However, the effect of copper upon non-amyloid Alzheimer’s pathology is relatively under-explored.Objective:To determine if modulation of brain copper level affects brain tau pathology and/or associated cognitive impairment.Methods:We tested the hypothesis that brain copper modulates tau pathology by manipulating brain levels of copper in the PS19 transgenic mouse model of tau pathology. We treated PS19 and wild-type mice with oral zinc acetate, an established therapy for long term control of excess brain copper, and examined treatment effects upon brain copper, brain tau, NFT-like pathology, and spatial memory. We treated a second cohort of mice with exogenous dietary copper in order to evaluate whether excess environmental copper promotes brain tau pathology.Results:Copper-lowering with oral zinc attenuated spatial memory impairment in female but not male PS19 mice, without a significant effect upon tau pathology. Copper loading increased brain copper, but did not have an effect on brain tau pathology or spatial memory function.Conclusion:These findings suggest that a strategy to lower brain copper may be viable for symptomatic benefit in the setting of tau neuropathology, but unlikely to have robust effects on the underlying pathology. These findings are consistent with dietary or other exogenous copper being unlikely to promote tau pathology.
Collapse
Affiliation(s)
- Christopher J Harris
- Department of Neurology, Oregon Health and Science University, Portland, OR, USA
| | - Nora E Gray
- Department of Neurology, Oregon Health and Science University, Portland, OR, USA
| | - Maya Caruso
- Department of Neurology, Oregon Health and Science University, Portland, OR, USA
| | - Marguex Hunter
- Department of Neurology, Oregon Health and Science University, Portland, OR, USA
| | - Martina Ralle
- Department of Neurology, Oregon Health and Science University, Portland, OR, USA
| | - Joseph F Quinn
- Department of Neurology, Oregon Health and Science University, Portland, OR, USA.,Parkinsons Disease Research, Education, and Clinical Center, Portland Veterans Affairs Medical Center, Portland, OR, USA
| |
Collapse
|
19
|
Zedda A, Gusai E, Caruso M, Bertuletti S, Baldazzi G, Spanu S, Riboni D, Pibiri A, Monticone M, Cereatti A, Pani D. DoMoMEA: a Home-Based Telerehabilitation System for Stroke Patients. Annu Int Conf IEEE Eng Med Biol Soc 2020; 2020:5773-5776. [PMID: 33019286 DOI: 10.1109/embc44109.2020.9175742] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
After a cerebral stroke, survivors need to follow a neurorehabilitation program including exercises to be executed under a therapist's supervision or autonomously. Technological solutions are needed to support the early discharge of the patients just after the primary hospital treatments, by still providing an adequate level of rehabilitation. The DoMoMEA Project proposes a fully-wearable m-health solution able to administer a neurorehabilitation therapy in the patient's home or every other place established by the patient for a rehabilitation session. The exploitation of magneto-inertial measurement units only, wirelessly connected to an Android-operated device, provides robustness to different operating conditions and immunity to optical occlusion problems, compared to RGB-D cameras. Patients' engagement is fostered by the exploitation of the exergame version of the ten rehabilitation exercises, implemented in Unity 3D. Store-and-forward telemonitoring features, supported by cloud-based storage and by a web application accessible from anywhere by medical personnel and patients, enable constant transparent monitoring of the rehabilitation progresses. The clinical trial of the DoMoMEA telerehabilitation system will involve 40 post-stroke patients with mild impairment and will start as soon as the restrictions due to the COVID-19 pandemic will allow to enroll patients.
Collapse
|
20
|
Caruso M, Sabatini AM, Knaflitz M, Gazzoni M, Croce UD, Cereatti A. Accuracy of the Orientation Estimate Obtained Using Four Sensor Fusion Filters Applied to Recordings of Magneto-Inertial Sensors Moving at Three Rotation Rates. Annu Int Conf IEEE Eng Med Biol Soc 2020; 2019:2053-2058. [PMID: 31946305 DOI: 10.1109/embc.2019.8857655] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Magneto-Inertial technology is a well-established alternative to optical motion capture for human motion analysis applications since it allows prolonged monitoring in free-living conditions. Magneto and Inertial Measurement Units (MIMUs) integrate a triaxial accelerometer, a triaxial gyroscope and a triaxial magnetometer in a single and lightweight device. The orientation of the body to which a MIMU is attached can be obtained by combining its sensor readings within a sensor fusion framework. Despite several sensor fusion implementations have been proposed, no well-established conclusion about the accuracy level achievable with MIMUs has been reached yet. The aim of this preliminary study was to perform a direct comparison among four popular sensor fusion algorithms applied to the recordings of MIMUs rotating at three different rotation rates, with the orientation provided by a stereophotogrammetric system used as a reference. A procedure for suboptimal determination of the parameter filter values was also proposed. The findings highlighted that all filters exhibited reasonable accuracy (rms errors <; 6.4°). Moreover, in accordance with previous studies, every algorithm's accuracy worsened as the rotation rate increased. At the highest rotation rate, the algorithm from Sabatini (2011) showed the best performance with errors smaller than 4.1° rms.
Collapse
|
21
|
Zweig JA, Caruso M, Brandes MS, Gray NE. Loss of NRF2 leads to impaired mitochondrial function, decreased synaptic density and exacerbated age-related cognitive deficits. Exp Gerontol 2019; 131:110767. [PMID: 31843395 DOI: 10.1016/j.exger.2019.110767] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2019] [Revised: 10/15/2019] [Accepted: 10/29/2019] [Indexed: 12/14/2022]
Abstract
Activation of the antioxidant regulatory transcription factor NRF2 (Nuclear factor erythroid-derived 2) regulates cellular bioenergetics and improves neuronal health in aging. Yet how NRF2 participates in maintaining synaptic, mitochondrial and cognitive function has not been fully elucidated. This study investigates how loss of NRF2 affects neuronal metabolism, synaptic density and cognitive performance in aged mice. Dendritic arborization as well as synaptic and mitochondrial gene expression was evaluated in hippocampal neurons isolated from mice lacking NRF2 (NRF2KO) and from wild-type (WT) C57BL6 mice. Mitochondrial function of these neurons was evaluated using the Seahorse XF platform. Additionally learning, memory and executive function were assessed in 20 month old NRF2KO and age-matched WT mice using conditioned fear response (CFR) and odor discrimination reversal learning (ODRL) tests. Hippocampal bioenergetics was profiled using mitochondria isolated from these animals and tissue was harvested for assessment of mitochondrial and synaptic genes. NRF2KO neurons had reduced dendritic complexity and diminished synaptic gene expression. This was accompanied by impaired mitochondrial function and decreased mitochondrial gene expression. Similar mitochondrial deficits were observed in the brains of aged NRF2KO mice. These animals also had significantly impaired cognitive performance and reduced synaptic gene expression as well. These data point to a role for NRF2 in maintaining mitochondrial and cognitive function during aging and suggest that the transcription factor may be a viable target for cognitive enhancing interventions. Because mitochondrial dysfunction and cognitive impairment also occur together in many neurodegenerative conditions there may be broad therapeutic potential of NRF2 activating agents.
Collapse
Affiliation(s)
- Jonathan A Zweig
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
| | - Maya Caruso
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
| | - Mikah S Brandes
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
| | - Nora E Gray
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA.
| |
Collapse
|
22
|
Matthews DG, Caruso M, Murchison CF, Zhu JY, Wright KM, Harris CJ, Gray NE, Quinn JF, Soumyanath A. Centella Asiatica Improves Memory and Promotes Antioxidative Signaling in 5XFAD Mice. Antioxidants (Basel) 2019; 8:antiox8120630. [PMID: 31817977 PMCID: PMC6943631 DOI: 10.3390/antiox8120630] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2019] [Revised: 12/03/2019] [Accepted: 12/06/2019] [Indexed: 12/11/2022] Open
Abstract
Centella asiatica (CA) herb is a traditional medicine, long reputed to provide cognitive benefits. We have reported that CA water extract (CAW) treatment improves cognitive function of aged Alzheimer’s disease (AD) model Tg2576 and wild-type (WT) mice, and induces an NRF2-regulated antioxidant response in aged WT mice. Here, CAW was administered to AD model 5XFAD female and male mice and WT littermates (age: 7.6 +/− 0.6 months), and object recall and contextual fear memory were tested after three weeks treatment. CAW’s impact on amyloid-β plaque burden, and markers of neuronal oxidative stress and synaptic density, was assessed after five weeks treatment. CAW antioxidant activity was evaluated via nuclear transcription factor (erythroid-derived 2)-like 2 (NRF2) and NRF2-regulated antioxidant response element gene expression. Memory improvement in both genders and genotypes was associated with dose-dependent CAW treatment without affecting plaque burden, and marginally increased synaptic density markers in the hippocampus and prefrontal cortex. CAW treatment increased Nrf2 in hippocampus and other NRF2 targets (heme oxygenase-1, NAD(P)H quinone dehydrogenase 1, glutamate-cysteine ligase catalytic subunit). Reduced plaque-associated SOD1, an indicator of oxidative stress, was observed in the hippocampi and cortices of CAW-treated 5XFAD mice. We postulate that CAW treatment leads to reduced oxidative stress, contributing to improved neuronal health and cognition.
Collapse
Affiliation(s)
- Donald G Matthews
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA; (D.G.M.); (M.C.); (C.F.M.); (J.Y.Z.); (K.M.W.); (C.J.H.); (N.E.G.); (J.F.Q.)
| | - Maya Caruso
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA; (D.G.M.); (M.C.); (C.F.M.); (J.Y.Z.); (K.M.W.); (C.J.H.); (N.E.G.); (J.F.Q.)
| | - Charles F Murchison
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA; (D.G.M.); (M.C.); (C.F.M.); (J.Y.Z.); (K.M.W.); (C.J.H.); (N.E.G.); (J.F.Q.)
- Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL 35294, USA
| | - Jennifer Y Zhu
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA; (D.G.M.); (M.C.); (C.F.M.); (J.Y.Z.); (K.M.W.); (C.J.H.); (N.E.G.); (J.F.Q.)
| | - Kirsten M Wright
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA; (D.G.M.); (M.C.); (C.F.M.); (J.Y.Z.); (K.M.W.); (C.J.H.); (N.E.G.); (J.F.Q.)
| | - Christopher J Harris
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA; (D.G.M.); (M.C.); (C.F.M.); (J.Y.Z.); (K.M.W.); (C.J.H.); (N.E.G.); (J.F.Q.)
- Parkinson’s Disease Research Education and Clinical Care Center, Veterans’ Administration Portland Health Care System, Portland, OR 97239, USA
| | - Nora E Gray
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA; (D.G.M.); (M.C.); (C.F.M.); (J.Y.Z.); (K.M.W.); (C.J.H.); (N.E.G.); (J.F.Q.)
| | - Joseph F Quinn
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA; (D.G.M.); (M.C.); (C.F.M.); (J.Y.Z.); (K.M.W.); (C.J.H.); (N.E.G.); (J.F.Q.)
- Parkinson’s Disease Research Education and Clinical Care Center, Veterans’ Administration Portland Health Care System, Portland, OR 97239, USA
| | - Amala Soumyanath
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA; (D.G.M.); (M.C.); (C.F.M.); (J.Y.Z.); (K.M.W.); (C.J.H.); (N.E.G.); (J.F.Q.)
- Correspondence: ; Tel.: +1-503-494-6878
| |
Collapse
|
23
|
De Marzo V, Parisi AR, Donahue M, D'Amario D, Annibali G, Manganiello V, Caruso M, Ielasi A, Misuraca L, Altamura L, Cortese B, Canepa M, Porto I. P2801Hard events after orsiro sirolimus-eluting stent (HEROES) in STEMI: a multicenter registry. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.1114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Primary percutaneous coronary intervention (pPCI) using drug-eluting stents (DES) is the treatment of choice for the ST segment elevation Myocardial infarction (STEMI). Specific DES platforms, as well the strategies used to control drug release, may influence mid-to-long term pPCI success rate.
Orsiro, a third generation hybrid sirolimus eluting stent with a biodegradable polymer, may potentially cause less stent malapposition, stent-induced inflammation and mechanical damage, ultimately reducing the thrombogenicity of the stent.
Purpose
The aim of the HEROES Registry is: 1) to evaluate the safety and efficacy of the Orsiro stent in STEMI patients undergoing pPCI; 2) to capture data that reflect the “real-world” use of Orsiro stents in pPCI and provide insights into patient characteristics, comorbid conditions, patterns of care, quality of care and performance measurements.
Methods
From January 2012 to March 2018 we prospectively enrolled all patients diagnosed with STEMI who have received one or more Orsiro stents in the target vessel of pPCI at 9 Italian centres.
The primary end-point of the study was a device-oriented composite end-point (DOCE) of cardiac death, any myocardial infarction (MI) clearly attributable to the intervention culprit vessel (TVMI) and ischemic-driven target lesion revascularization (ID-TLR) at 1-year follow up.
Secondary end-points were: 1) DOCE at 6-month and 3-year follow-ups; 2) any definite/probable stent thrombosis; 3) any TIMI major bleeding (in-hospital, within 7 days after pPCI and at follow-up).
Results
Study cohort comprised 338 patients with a mean age of 64.9±12.0 years; 255 (75.4%) were men, 69 (20.4%) had diabetes and 59 (17.5%) chronic kidney disease. Median follow-up was 10.5 (range 0–67) months. Culprit vessel was the left anterior descending (LAD) in 167 (49.4%), right coronary (RCA) in 97 (28.7%), left circumflex artery (LCX) in 42 (12.4%) and other vessels in 32 (9.5%). Multivessel disease was present in 178 (52.7%); 106 (31.4%) had bifurcation lesion as a culprit. In 155 (45.9%) the culprit lesion was proximal, in 154 (45.6%) mid-vessel. Stent per lesion ratio was 1.3±0.6. Thrombus grade was 0–2 in 236 (69.8%) and 3–5 in 102 (30.2%).
At 1-year follow-up we observed a 4.4% cumulative incidence of DOCE, consisting of 13 (3.8%) cardiac deaths, 1 (0.3%) TVMI and 1 (0.3%) ID-TLR. Definite stent thrombosis occurred in only 1 (0.3%) patient during hospital stay. There were only 4 major bleedings (1.2%), all during follow-up.
Kaplan-Meier analysis showed a DOCE-free survival at 6 months of 95.9%, and at 1 and 3 years of 95.6 and 95%, respectively.
DOCE-free survival curve
Conclusions
Orsiro stent seems to be effective and safe in contemporary pPCI. The optimal features of Orsiro contribute to the few adverse events observed during follow-up and to an event-free survival that compares favorably with similar registries of modern DES.
Collapse
Affiliation(s)
| | - A R Parisi
- AO Ospedali Riuniti Marche Nord, Pesaro, Italy
| | - M Donahue
- Polyclinic Casilino of Rome, Rome, Italy
| | - D D'Amario
- Polyclinic Agostino Gemelli, Rome, Italy
| | - G Annibali
- Polyclinic Agostino Gemelli, Rome, Italy
| | | | | | - A Ielasi
- Bolognini Hospital, Seriate, Italy
| | | | | | - B Cortese
- Fatebenefratelli Hospital, Milan, Italy
| | - M Canepa
- San Martino Hospital, Genova, Italy
| | - I Porto
- San Martino Hospital, Genova, Italy
| |
Collapse
|
24
|
Sahlem G, Caruso M, Malcolm R, George M, McRae-Clark A. A case series exploring the effect of twenty sessions of repetitive transcranial magnetic stimulation (rTMS) on cannabis use and craving. Brain Stimul 2019. [DOI: 10.1016/j.brs.2018.12.428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
25
|
Tariq K, Schofield JPR, Nicholas BL, Burg D, Brandsma J, Bansal AT, Wilson SJ, Lutter R, Fowler SJ, Bakke, Caruso M, Dahlen B, Horváth I, Krug N, Montuschi P, Sanak M, Sandström T, Geiser T, Pandis I, Sousa AR, Adcock IM, Shaw DE, Auffray C, Howarth PH, Sterk PJ, Chung KF, Skipp PJ, Dimitrov B, Djukanović R. Sputum proteomic signature of gastro-oesophageal reflux in patients with severe asthma. Respir Med 2019; 150:66-73. [PMID: 30961953 DOI: 10.1016/j.rmed.2019.02.008] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/29/2018] [Revised: 01/30/2019] [Accepted: 02/04/2019] [Indexed: 01/08/2023]
Abstract
Gastro-oesophageal reflux disease (GORD) has long been associated with poor asthma control without an established cause-effect relationship. 610 asthmatics (421 severe/88 mild-moderate) and 101 healthy controls were assessed clinically and a subset of 154 severe asthmatics underwent proteomic analysis of induced sputum using untargeted mass spectrometry, LC-IMS-MSE. Univariate and multiple logistic regression analyses (MLR) were conducted to identify proteins associated with GORD in this cohort. When compared to mild/moderate asthmatics and healthy individuals, respectively, GORD was three- and ten-fold more prevalent in severe asthmatics and was associated with increased asthma symptoms and oral corticosteroid use, poorer quality of life, depression/anxiety, obesity and symptoms of sino-nasal disease. Comparison of sputum proteomes in severe asthmatics with and without active GORD showed five differentially abundant proteins with described roles in anti-microbial defences, systemic inflammation and epithelial integrity. Three of these were associated with active GORD by multiple linear regression analysis: Ig lambda variable 1-47 (p = 0·017) and plasma protease C1 inhibitor (p = 0·043), both in lower concentrations, and lipocalin-1 (p = 0·034) in higher concentrations in active GORD. This study provides evidence which suggests that reflux can cause subtle perturbation of proteins detectable in the airways lining fluid and that severe asthmatics with GORD may represent a distinct phenotype of asthma.
Collapse
Affiliation(s)
- K Tariq
- NIHR Southampton Respiratory Biomedical Research Centre, University Hospital Southampton, Southampton, UK; Clinical Experimental Sciences Unit, Faculty of Medicine, University of Southampton, University Hospital Southampton, South Academic Block, Southampton, UK
| | - J P R Schofield
- NIHR Southampton Respiratory Biomedical Research Centre, University Hospital Southampton, Southampton, UK; Centre for Proteomic Research, University of Southampton, Highfield, Southampton, UK
| | - B L Nicholas
- NIHR Southampton Respiratory Biomedical Research Centre, University Hospital Southampton, Southampton, UK; Clinical Experimental Sciences Unit, Faculty of Medicine, University of Southampton, University Hospital Southampton, South Academic Block, Southampton, UK
| | - D Burg
- NIHR Southampton Respiratory Biomedical Research Centre, University Hospital Southampton, Southampton, UK; Centre for Proteomic Research, University of Southampton, Highfield, Southampton, UK
| | - J Brandsma
- NIHR Southampton Respiratory Biomedical Research Centre, University Hospital Southampton, Southampton, UK
| | | | - S J Wilson
- NIHR Southampton Respiratory Biomedical Research Centre, University Hospital Southampton, Southampton, UK
| | - R Lutter
- AMC, Department of Experimental Immunology, University of Amsterdam, Amsterdam, the Netherlands; AMC, Department of Respiratory Medicine, University of Amsterdam, Amsterdam, the Netherlands
| | - S J Fowler
- Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester and University Hospital of South Manchester, NHS Foundation Trust, Manchester, UK
| | - Bakke
- Department of Clinical Science, University of Bergen, Bergen, Norway
| | - M Caruso
- Dept. of Clinical and Experimental Medicine Hospital University, Policlinico-Vittorio Emanuele, University of Catania, Catania, Italy
| | - B Dahlen
- Division of Respiratory Medicine and Allergy, Department of Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden
| | - I Horváth
- Dept. of Pulmonology, Semmelweis University, Budapest, Hungary
| | - N Krug
- Fraunhofer Institute for Toxicology and Experimental Medicine Hannover, Hannover, Germany
| | - P Montuschi
- Dept. of Pharmacology, Faculty of Medicine, Catholic University of the Sacred Heart, Rome, Italy
| | - M Sanak
- Division of Molecular Biology and Clinical Genetics, Medical College, Jagiellonian University Medical College, Krakow, Poland
| | - T Sandström
- Dept. of Medicine, Dept of Public Health and Clinical Medicine Respiratory Medicine Unit, Umeå University, Umeå, Sweden
| | - T Geiser
- University Hospital Bern, Bern, Switzerland
| | - I Pandis
- Data Science Institute, Imperial College, London, UK
| | - A R Sousa
- Respiratory Therapeutic Unit, GSK, Stockley Park, UK
| | - I M Adcock
- Cell and Molecular Biology Group, Airways Disease Section, National Heart and Lung Institute, Imperial College London, Dovehouse Street, London, UK
| | - D E Shaw
- Respiratory Research Unit, University of Nottingham, Nottingham, UK
| | - C Auffray
- European Institute for Systems Biology and Medicine, CNRS-ENS-UCBL-INSERM, Lyon, France
| | - P H Howarth
- NIHR Southampton Respiratory Biomedical Research Centre, University Hospital Southampton, Southampton, UK; Clinical Experimental Sciences Unit, Faculty of Medicine, University of Southampton, University Hospital Southampton, South Academic Block, Southampton, UK
| | - P J Sterk
- AMC, Department of Respiratory Medicine, University of Amsterdam, Amsterdam, the Netherlands
| | - K F Chung
- Airways Disease, National Heart and Lung Institute, Imperial College, London & Royal Brompton NIHR Biomedical Research Unit, London, United Kingdom
| | - P J Skipp
- Centre for Proteomic Research, University of Southampton, Highfield, Southampton, UK
| | - B Dimitrov
- NIHR Southampton Respiratory Biomedical Research Centre, University Hospital Southampton, Southampton, UK
| | - R Djukanović
- NIHR Southampton Respiratory Biomedical Research Centre, University Hospital Southampton, Southampton, UK; Clinical Experimental Sciences Unit, Faculty of Medicine, University of Southampton, University Hospital Southampton, South Academic Block, Southampton, UK.
| | | |
Collapse
|
26
|
Radtke A, Caruso M, Miller A, Getman L. Treatment of a poorly differentiated sarcoma in the oropharynx of a horse. EQUINE VET EDUC 2018. [DOI: 10.1111/eve.13025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- A. Radtke
- Department of Clinical Sciences Cornell University College of Veterinary Medicine Ithaca New York USA
| | - M. Caruso
- Tennessee Equine Hospital Thompson's Station Tennessee USA
| | - A. Miller
- Department of Biomedical Sciences Section of Anatomic Pathology Cornell University College of Veterinary Medicine Ithaca New York USA
| | - L. Getman
- Tennessee Equine Hospital Thompson's Station Tennessee USA
| |
Collapse
|
27
|
Adamo V, Ricciardi G, Schifano S, Russo A, Gebbia V, Blasi L, Giuffrida D, Scandurra G, Savarino A, Butera A, Borsellino N, Verderame F, Caruso M. Nab-paclitaxel (nab-P) in metastatic breast cancer (MBC) in elderly patients: A real life setting (NEREIDE study). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy272.310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Gray NE, Zweig JA, Caruso M, Zhu JY, Wright KM, Quinn JF, Soumyanath A. Centella asiatica attenuates hippocampal mitochondrial dysfunction and improves memory and executive function in β-amyloid overexpressing mice. Mol Cell Neurosci 2018; 93:1-9. [PMID: 30253196 DOI: 10.1016/j.mcn.2018.09.002] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2018] [Revised: 09/17/2018] [Accepted: 09/20/2018] [Indexed: 12/21/2022] Open
Abstract
Centella asiatica is a medicinal plant used to enhance memory. We have previously shown that a water extract of Centella asiatica (CAW) attenuates β-amyloid (Aβ)-induced spatial memory deficits in mice and improves neuronal health. Yet the effect of CAW on other cognitive domains remains unexplored as does its in vivo mechanism of improving Aβ-related cognitive impairment. This study investigates the effects of CAW on learning, memory and executive function as well as mitochondrial function and antioxidant response in the 5xFAD model of Aβ accumulation. Seven month old 5xFAD female mice were treated with CAW (2 mg/mL) in their drinking water for two weeks prior to behavioral testing. Learning, memory and executive function were assessed using the object location memory task (OLM), conditioned fear response (CFR) and odor discrimination reversal learning (ODRL) test. Mitochondrial function was profiled using the Seahorse XF platform in hippocampal mitochondria isolated from these animals and tissue was harvested for assessment of mitochondrial, antioxidant and synaptic proteins. CAW improved performance in all behavioral tests in the 5xFAD but had no effect on WT animals. Hippocampal mitochondrial function was improved and hippocampal and cortical expression of mitochondrial genes was increased in CAW-treated 5xFAD mice. Gene expression of the transcription factor NRF2, as well as its antioxidant target enzymes, was also increased with CAW treatment in both WT and 5xFAD mice. CAW treatment also decreased Aβ-plaque burden in the hippocampus of treated 5xFAD mice but had no effect on plaques in the cortex. These data show that CAW can improve many facets of Aβ-related cognitive impairment in 5xFAD mice. Oral treatment with CAW also attenuates hippocampal mitochondrial dysfunction in these animals. Because mitochondrial dysfunction and oxidative stress accompany cognitive impairment in many pathological conditions beyond Alzheimer's disease, this suggests potentially broad therapeutic utility of CAW.
Collapse
Affiliation(s)
- Nora E Gray
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA.
| | - Jonathan A Zweig
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
| | - Maya Caruso
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
| | - Jennifer Y Zhu
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
| | - Kirsten M Wright
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
| | - Joseph F Quinn
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA; Department of Neurology and Parkinson's Disease Research Education and Clinical Care Center (PADRECC), VA Portland Healthcare System, Portland, OR 97239, USA
| | - Amala Soumyanath
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
| |
Collapse
|
29
|
Gray NE, Zweig JA, Caruso M, Martin MD, Zhu JY, Quinn JF, Soumyanath A. Centella asiatica increases hippocampal synaptic density and improves memory and executive function in aged mice. Brain Behav 2018; 8:e01024. [PMID: 29920983 PMCID: PMC6043711 DOI: 10.1002/brb3.1024] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/28/2018] [Revised: 05/07/2018] [Accepted: 05/08/2018] [Indexed: 12/27/2022] Open
Abstract
INTRODUCTION Centella asiatica is a plant used for centuries to enhance memory. We have previously shown that a water extract of Centella asiatica (CAW) attenuates age-related spatial memory deficits in mice and improves neuronal health. Yet the effect of CAW on other cognitive domains remains unexplored as does its mechanism of improving age-related cognitive impairment. This study investigates the effects of CAW on a variety of cognitive tasks as well as on synaptic density and mitochondrial and antioxidant pathways. METHODS Twenty-month-old CB6F1 mice were treated with CAW (2 mg/ml) in their drinking water for 2 weeks prior to behavioral testing. Learning, memory, and executive function were assessed using the novel object recognition task (NORT), object location memory task (OLM), and odor discrimination reversal learning (ODRL) test. Tissue was collected for Golgi analysis of spine density as well as assessment of mitochondrial, antioxidant, and synaptic proteins. RESULTS CAW improved performance in all behavioral tests suggesting effects on hippocampal and cortical dependent memory as well as on prefrontal cortex mediated executive function. There was also an increase in synaptic density in the treated animals, which was accompanied by increased expression of the antioxidant response gene NRF2 as well as the mitochondrial marker porin. CONCLUSIONS These data show that CAW can increase synaptic density as well as antioxidant and mitochondrial proteins and improve multiple facets of age-related cognitive impairment. Because mitochondrial dysfunction and oxidative stress also accompany cognitive impairment in many pathological conditions this suggests a broad therapeutic utility of CAW.
Collapse
Affiliation(s)
- Nora E Gray
- Department of Neurology, Oregon Health and Science University, Portland, Oregon
| | - Jonathan A Zweig
- Department of Neurology, Oregon Health and Science University, Portland, Oregon.,Department of Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, Oregon
| | - Maya Caruso
- Department of Neurology, Oregon Health and Science University, Portland, Oregon
| | - Marjoen D Martin
- Department of Neurology, Oregon Health and Science University, Portland, Oregon
| | - Jennifer Y Zhu
- Department of Neurology, Oregon Health and Science University, Portland, Oregon.,Department of Behavioral Neuroscience, Oregon Health and Science University, Portland, Oregon
| | - Joseph F Quinn
- Department of Neurology, Oregon Health and Science University, Portland, Oregon.,Department of Neurology and Parkinson's Disease Research Education and Clinical Care Center (PADRECC), VA Portland Healthcare System, Portland, Oregon
| | - Amala Soumyanath
- Department of Neurology, Oregon Health and Science University, Portland, Oregon
| |
Collapse
|
30
|
Matthews DG, Caruso M, Gray NE, Zhu JY, Wright KM, Quinn JF, Soumyanath A. P1‐084:
CENTELLA ASIATICA
IMPROVES MEMORY IN TG2576 AND 5XFAD MICE WITH GENDER‐DEPENDENT DIFFERENCES IN DOSE RESPONSE. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
| | - Maya Caruso
- Oregon Health and Science UniversityPortlandORUSA
| | - Nora E. Gray
- Oregon Health and Science UniversityPortlandORUSA
| | | | | | | | | |
Collapse
|
31
|
Lou JS, Dimitrova DM, Murchison C, Arnold GC, Belding H, Seifer N, Le N, Andrea SB, Gray NE, Wright KM, Caruso M, Soumyanath A. Centella asiatica triterpenes for diabetic neuropathy: a randomized, double-blind, placebo-controlled, pilot clinical study. Esper Dermatol 2018; 20:12-22. [PMID: 31080345 PMCID: PMC6510539 DOI: 10.23736/s1128-9155.18.00455-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Diabetic neuropathy (DN), a common complication of diabetes mellitus, results from hyperglycemia, poor microcirculation and attendant nerve damage. Currently available treatments relieve symptoms, but do not modify the neurodegeneration underlying DN. Centella asiatica (CA) triterpenes improved microcirculation in earlier clinical studies, and showed neurotropic effects in preclinical models suggesting a potential disease modifying effect in DN. This 52-week, randomized, double-blind, placebo-controlled trial examined the effects of CAST, a standardized CA extract containing triterpenes, on neuropathy symptoms in Type II diabetic subjects. PATIENTS AND METHODS The study enrolled patients with a history of Type II diabetes, with evidence of symptomatic symmetrical DN with total symptom score (TSS) ≥4, and stable HbA1c level <8. The primary outcome measure was TSS, which assessed intensity and frequency of parasthesia, numbness, pain and burning symptoms self-reported by patients. Secondary measures were nerve conduction, neurological impairment score, and quantitative sensory testing. RESULTS Comparing CAST (n=21) and Placebo (n=22) groups, significant reductions from baseline for TSS (p<0.01) and paresthesia (p<0.01) were seen only in CAST treated groups. Numbness increased from baseline only in the Placebo group (p<0.05) and was significantly higher than for the CAST group (p<0.001). Burning sensation was reduced in both groups (p<0.01). Plasma triterpene levels in patients treated with CAST mirrored neurotropic concentrations in vitro. CONCLUSIONS CAST is a potential oral treatment for diabetic neuropathy, as it is well tolerated and effective in reducing the severity of DN symptoms in patients with Type II diabetes.
Collapse
Affiliation(s)
- Jau-Shin. Lou
- Department of Neurology, Oregon Health and Science University, Portland, OR, 97239, USA
- Present address: University of North Dakota School of Medicine & Health Science, Fargo, ND 58103, USA
| | - Diana M. Dimitrova
- Department of Neurology, Oregon Health and Science University, Portland, OR, 97239, USA
| | - Charles Murchison
- Department of Neurology, Oregon Health and Science University, Portland, OR, 97239, USA
| | - Grace C. Arnold
- Department of Neurology, Oregon Health and Science University, Portland, OR, 97239, USA
| | - Heather Belding
- Department of Neurology, Oregon Health and Science University, Portland, OR, 97239, USA
| | - Nick Seifer
- Department of Neurology, Oregon Health and Science University, Portland, OR, 97239, USA
| | - Ngoc Le
- Department of Neurology, Oregon Health and Science University, Portland, OR, 97239, USA
| | - Sarah B. Andrea
- Department of Neurology, Oregon Health and Science University, Portland, OR, 97239, USA
| | - Nora E. Gray
- Department of Neurology, Oregon Health and Science University, Portland, OR, 97239, USA
| | - Kirsten M. Wright
- Department of Neurology, Oregon Health and Science University, Portland, OR, 97239, USA
| | - Maya Caruso
- Department of Neurology, Oregon Health and Science University, Portland, OR, 97239, USA
| | - Amala Soumyanath
- Department of Neurology, Oregon Health and Science University, Portland, OR, 97239, USA
| |
Collapse
|
32
|
Adamo V, Ricciardi G, Schifano S, Russo A, Gebbia V, Blasi L, Giuffrida D, Scandurra G, Savarino A, Butera A, Borsellino N, Verderame F, Caruso M. Safety and efficacy of the treatment with Nab-paclitaxel in mEtastaticbREast cancer In elDerlypatiEnts: NEREIDE Study. Eur J Cancer 2018. [DOI: 10.1016/s0959-8049(18)30567-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
33
|
Dakiw Piaceski A, Larouche D, Ghani K, Bisson F, Cortez Ghio S, Larochelle S, Moulin VJ, Caruso M, Germain L. Translating the combination of gene therapy and tissue engineering for treating recessive dystrophic epidermolysis bullosa. Eur Cell Mater 2018; 35:73-86. [PMID: 29441510 DOI: 10.22203/ecm.v035a06] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
The combination of gene therapy and tissue engineering is one of the most promising strategies for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). RDEB is a rare genetic disease characterised by mutations in the COL7A1 gene, encoding type VII collagen (COLVII), which forms anchoring fibrils at the dermal-epidermal junction of the skin. This disease causes severe blistering and only palliative treatments are offered. In this study, the base of a strategy combining gene therapy and a tissue-engineered skin substitute (TES), which would be suitable for the permanent closure of skin wounds, was set-up. As a high transduction efficiency into fibroblasts and/or keratinocytes seems to be a prerequisite for a robust and sustained correction of RDEB, different envelope pseudotyped retroviral vectors and the transduction enhancer EF-C were tested. When green fluorescent protein (GFP) was used as a reporter gene to evaluate the retroviral-mediated gene transfer, the fibroblast infection efficiency was 30 % higher with the Ampho pseudotyped vector as compared with the other pseudotypes. At least a 3.1-fold and a 1.3-fold increased transduction were obtained in fibroblasts and keratinocytes, respectively, with EF-C as compared with polybrene. A continuous and intense deposit of haemagglutinin (HA)-COLVII was observed at the dermal-epidermal junction of self-assembled TESs made of cells transduced with a HA-tagged COL7A1 vector. Furthermore, HA-tagged basal epidermal cells expressing keratin 19 were observed in TESs, suggesting stem cell transduction. This approach could be a valuable therapeutic option to further develop, in order to improve the long-term life quality of RDEB patients.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - M Caruso
- Cancer Research Centre, Université Laval, Quebec City, Quebec, G1R 3S3, Canada.Manuel.Caruso@ crchudequebec.ulaval.ca
| | | |
Collapse
|
34
|
Maugeri AG, Barchitta M, Quattrocchi A, La Rosa MC, Caruso M, Panella M, Cianci A, Agodi A. Mediterranean diet, nutrient intakes and pregnancy: results from a Sicilian mother-child cohort. Eur J Public Health 2017. [DOI: 10.1093/eurpub/ckx189.251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- AG Maugeri
- Department GF Ingrassia, University of Catania, Catania, Italy
| | - M Barchitta
- Department GF Ingrassia, University of Catania, Catania, Italy
| | - A Quattrocchi
- Department GF Ingrassia, University of Catania, Catania, Italy
| | - MC La Rosa
- Department GF Ingrassia, University of Catania, Catania, Italy
| | - M Caruso
- Azienda Ospedaliero-Universitaria “Policlinico - Vittorio Emanuele”, Catania, Italy
| | - M Panella
- Azienda Ospedaliero-Universitaria “Policlinico - Vittorio Emanuele”, Catania, Italy
| | - A Cianci
- Azienda Ospedaliero-Universitaria “Policlinico - Vittorio Emanuele”, Catania, Italy
| | - A Agodi
- Department GF Ingrassia, University of Catania; AOU Policlinico V Emanuele, Catania, Italy
| |
Collapse
|
35
|
Adamo V, Ricciardi G, Schifano S, Russo A, Gebbia V, Blasi L, Giuffrida D, Scandurra G, Savarino A, Butera A, Borsellino N, Verderame F, Caruso M. Safety and efficacy of the treatment with Nab-paclitaxel in mEtastatic bREast cancer In elDerly patiEnts: NEREIDE study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx424.054] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Zizzadoro C, Caruso M, Punzi S, Crescenzo G, Zongoli F, Belloli C. A comparative study between responses of isolated bovine and equine digital arteries to vasoactive mediators. J Vet Pharmacol Ther 2017; 41:51-59. [DOI: 10.1111/jvp.12436] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2016] [Accepted: 06/07/2017] [Indexed: 01/17/2023]
Affiliation(s)
- C. Zizzadoro
- Division of Veterinary Pharmacology and Toxicology; Department of Veterinary Medicine; University of Bari; Valenzano Bari Italy
| | - M. Caruso
- Division of Veterinary Pharmacology and Toxicology; Department of Veterinary Medicine; University of Bari; Valenzano Bari Italy
| | - S. Punzi
- Division of Veterinary Pharmacology and Toxicology; Department of Veterinary Medicine; University of Bari; Valenzano Bari Italy
| | - G. Crescenzo
- Division of Veterinary Pharmacology and Toxicology; Department of Veterinary Medicine; University of Bari; Valenzano Bari Italy
| | | | - C. Belloli
- Division of Veterinary Pharmacology and Toxicology; Department of Veterinary Medicine; University of Bari; Valenzano Bari Italy
| |
Collapse
|
37
|
Gray NE, Zweig JA, Murchison C, Caruso M, Matthews DG, Kawamoto C, Harris CJ, Quinn JF, Soumyanath A. Centella asiatica attenuates Aβ-induced neurodegenerative spine loss and dendritic simplification. Neurosci Lett 2017; 646:24-29. [PMID: 28279707 DOI: 10.1016/j.neulet.2017.02.072] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2016] [Revised: 02/21/2017] [Accepted: 02/27/2017] [Indexed: 01/13/2023]
Abstract
The medicinal plant Centella asiatica has long been used to improve memory and cognitive function. We have previously shown that a water extract from the plant (CAW) is neuroprotective against the deleterious cognitive effects of amyloid-β (Aβ) exposure in a mouse model of Alzheimer's disease, and improves learning and memory in healthy aged mice as well. This study explores the physiological underpinnings of those effects by examining how CAW, as well as chemical compounds found within the extract, modulate synaptic health in Aβ-exposed neurons. Hippocampal neurons from amyloid precursor protein over-expressing Tg2576 mice and their wild-type (WT) littermates were used to investigate the effect of CAW and various compounds found within the extract on Aβ-induced dendritic simplification and synaptic loss. CAW enhanced arborization and spine densities in WT neurons and prevented the diminished outgrowth of dendrites and loss of spines caused by Aβ exposure in Tg2576 neurons. Triterpene compounds present in CAW were found to similarly improve arborization although they did not affect spine density. In contrast caffeoylquinic acid (CQA) compounds from CAW were able to modulate both of these endpoints, although there was specificity as to which CQAs mediated which effect. These data suggest that CAW, and several of the compounds found therein, can improve dendritic arborization and synaptic differentiation in the context of Aβ exposure which may underlie the cognitive improvement observed in response to the extract in vivo. Additionally, since CAW, and its constituent compounds, also improved these endpoints in WT neurons, these results may point to a broader therapeutic utility of the extract beyond Alzheimer's disease.
Collapse
Affiliation(s)
- Nora E Gray
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA.
| | - Jonathan A Zweig
- Department of Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR 97239, USA
| | - Charles Murchison
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
| | - Maya Caruso
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
| | - Donald G Matthews
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
| | - Colleen Kawamoto
- Department of Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR 97239, USA
| | - Christopher J Harris
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
| | - Joseph F Quinn
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA; Department of Neurology and Parkinson's Disease Research Education and Clinical Care Center (PADRECC), Portland Veterans Affairs Medical Center, Portland, OR 97239, USA
| | - Amala Soumyanath
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
| |
Collapse
|
38
|
Fabi A, De Laurentiis M, Caruso M, Valle E, Moscetti L, Santini D, Cannita K, Carbognin L, Ciccarese M, Rossello R, Arpino G, Leonardi V, Montemurro F, La Verde N, Generali DG, Zambelli A, Scandurra G, Russillo M, Paris I, D'Ottavio AM, Filippelli G, Giampaglia M, Stani S, Fabbri A, Alesini D, Giannarelli D, Cognetti F. Abstract P4-21-11: T-DM1 in HER2 positive advanced breast cancer patients: Real world practice from a multicenter observational study. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-21-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: T-DM1 showed remarkable activity in metastatic HER-2 positive breast cancer (mBC) and it was recently approved for clinical use in patients (pts) who previously failed Trastuzumab- and Taxanes-based therapies. Currently, little is known on the performance of T-DM1 in a “real life” scenario. Therefore, we investigated effectiveness and safety of T-DM1 in Italian daily practice.
Methods: Pts baseline characteristics and clinical outcome of pts with HER-2 positive mBC treated with T-DM1 between 2013 and 2015 at 20 Italian Institutions were retrospectively collected and analyzed.
Results: 300 pts were included in our analysis. Median age was 51 years (27-78); visceral metastases were present in 204 (68%) pts and brain metastases in 86 (29%). It is noteworthy that 111 (37%) pts received T-DM1 as pure second line, 83 (28%) as third line and 96 (32%) as further lines. Moreover 10 (3%) pts had T-DM1 as first line because disease recurrence occurred during or adjuvant trastuzumab of within 6 months of its completion. The overall response rate (ORR) was 40%, global disease control rate (gDCR) 64%, median progression-free survival (PFS) 7.0 months (C.I.95%: 5.6-8.4) and overall survival (OS) at 2 years 63%. Pts with 1, 2 and 3 or more metastatic site had OS at 2 years of 87%, 67% and 46%, respectively (p<0.0001). When T-DM1 was given as second line the PFS was 8.0 months and beyond second-line was 6.8 months. Interestingly, for 38 (13%) pts who progressed after Pertuzumab-plus trastuzumab and taxanes as first line treatment, ORR and gDCR were similar to pertuzumab-naïve patients (38% and 62%, respectively) However PFS was 5.0 months (C.I.95%: 4.3-5.7) compared to 9.0 (95% C.I. 5.5-12.4) achieved in pts not receiving a previous pertuzumab-based treatment. Most frequent grade ≥3 toxicities were thrombocytopenia (2.6%), alopecia (2.1%), hypertransaminasemia (2.2%), neutropenia (1.3%), asthenia (1.3%) and diarrhea (0.4%).
Conclusions: To our knowledge, this is the first real life, multicenter retrospective analysis evaluating efficacy and safety of T-DM1 in pretreated HER-2 positive mBC pts. We observed remarkable results in terms of PFS and OS, especially when T-DM1 was given early in the course of metastatic disease. Shortened PFS in patients progressing after pertuzumab suggest further analyses to better define possible molecular mechanisms of cross-resistences between two molecules. As a whole there was no evidence of significant or unexpected toxicities. Although these findings should be taken with caution due to the retrospective analysis and the different lines of previous treatment considered, we confirmed the potential therapeutic role of T-DM1 across a heterogeneous population of HER-2 positive mBC patients. The final analysis will be presented to the meeting.
Citation Format: Fabi A, De Laurentiis M, Caruso M, Valle E, Moscetti L, Santini D, Cannita K, Carbognin L, Ciccarese M, Rossello R, Arpino G, Leonardi V, Montemurro F, La Verde N, Generali DG, Zambelli A, Scandurra G, Russillo M, Paris I, D'Ottavio AM, Filippelli G, Giampaglia M, Stani S, Fabbri A, Alesini D, Giannarelli D, Cognetti F. T-DM1 in HER2 positive advanced breast cancer patients: Real world practice from a multicenter observational study [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-21-11.
Collapse
Affiliation(s)
- A Fabi
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - M De Laurentiis
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - M Caruso
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - E Valle
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - L Moscetti
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - D Santini
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - K Cannita
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - L Carbognin
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - M Ciccarese
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - R Rossello
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - G Arpino
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - V Leonardi
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - F Montemurro
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - N La Verde
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - DG Generali
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - A Zambelli
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - G Scandurra
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - M Russillo
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - I Paris
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - AM D'Ottavio
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - G Filippelli
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - M Giampaglia
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - S Stani
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - A Fabbri
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - D Alesini
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - D Giannarelli
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - F Cognetti
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| |
Collapse
|
39
|
Marinari S, De Iuliis V, Dadorante V, Colella S, Marino A, Nunziata A, Flati V, Caruso M, Pennelli A, De Benedetto F, Matera S, Capodifoglio S, Martinotti S, Caputi S, Toniato E. Cytokine modulation in patients with idiopathic pulmonary fibrosis undergoing treatment with steroids, immunosuppressants, and IFN-γ 1b. J BIOL REG HOMEOS AG 2017; 31:59-69. [PMID: 28337871] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease of unknown etiology and pathogenic mechanisms. From an etiopathogenic point of view, alveolar macrophages play a key role in accumulation of fibroblasts and deposition of collagen and extracellular matrix by releasing specific cytokines and inflammatory mediators. IPF seems to be also associated with circulating fibrocytes, which might be involved with an abnormal pulmonary vascular repair and remodeling. Based on its hypothesized pathologic mechanisms, anti-inflammatory, anti-fibrotic and immunosuppressive therapies are often used. For these reasons, Interferon-g (IFN-g) has been used to exploit its activity on macrophages and fibroblasts. The aim of this study was to investigate the response to corticosteroids and/or IFN-g 1b treatments based on pulmonary function tests and on inflammatory cytokine patterns of expression on bronchoalveolar lavage (BAL), at baseline and during and after the therapies. Unlike previous studies, we analyzed a period of therapy longer than 1 year. Our results demonstrated the effectiveness of IFN-γ in a group of IPF patients in whom the treatment was prolonged for over a year. These data suggest a positive role of IFN-γ; treatment in patients in the initial stage of the disease.
Collapse
Affiliation(s)
- S Marinari
- SS Annunziata University Hospital, Unit of Pneumology, Chieti, Italy
| | - V De Iuliis
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Italy
| | - V Dadorante
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti
| | - S Colella
- SS Annunziata University Hospital, Unit of Pneumology, Chieti, Italy
| | - A Marino
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Italy
| | - A Nunziata
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Italy
| | - V Flati
- Department of Biotechnological and Applied Clinical Sciences, University of LAquila, Italy
| | - M Caruso
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Italy
| | - A Pennelli
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti
| | - F De Benedetto
- AIMAR (Interdisciplinary Association for the study of Respiratory Diseases), Arona (NO), Italy
| | - S Matera
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Italy
| | - S Capodifoglio
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Italy
| | - S Martinotti
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Italy
| | - S Caputi
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Italy
| | - E Toniato
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Italy
| |
Collapse
|
40
|
Caruso M, Fanchiotti H, García Canal CA, Mayosky M, Veiga A. The quantum CP-violating kaon system reproduced in the electronic laboratory. Proc Math Phys Eng Sci 2016. [DOI: 10.1098/rspa.2016.0615] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The equivalence between the Schrödinger dynamics of a quantum system with a finite number of basis states and a classical dynamics is realized in terms of electric networks. The isomorphism that connects in a univocal way both dynamical systems was applied to the case of neutral mesons, kaons in particular, and the class of electric networks univocally related to the quantum system was analysed. Moreover, under
CPT
invariance, the relevant
ϵ
parameter that measures
CP
violation in the kaon system is reinterpreted in terms of network parameters. All these results were explicitly shown by means of both a numerical simulation of the implied networks and by constructing the corresponding circuits.
Collapse
Affiliation(s)
- M. Caruso
- Laboratorio de Física Teórica, Departamento de Física, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, IFLP-CONICET, C.C. 67, 1900 La Plata, Argentina
| | - H. Fanchiotti
- Laboratorio de Física Teórica, Departamento de Física, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, IFLP-CONICET, C.C. 67, 1900 La Plata, Argentina
| | - C. A. García Canal
- Laboratorio de Física Teórica, Departamento de Física, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, IFLP-CONICET, C.C. 67, 1900 La Plata, Argentina
| | - M. Mayosky
- LEICI, Departamento de Electrotecnia Facultad de Ingeniería, Universidad Nacional de La Plata, La Plata, Argentina. Comisión de Investigaciones Científicas de la Provincia de Buenos Aires-CICpBA, , Argentina
| | - A. Veiga
- LEICI, Departamento de Electrotecnia Facultad de Ingeniería, Universidad Nacional de La Plata, CONICET, La Plata, Argentina
| |
Collapse
|
41
|
Imburgia A, Romano P, Caruso M, Viola F, Miceli R, Riva Sanseverino E, Madonia A, Schettino G. Contributed Review: Review of thermal methods for space charge measurement. Rev Sci Instrum 2016; 87:111501. [PMID: 27910572 DOI: 10.1063/1.4968029] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
The space charge accumulation phenomenon has garnered great interest over the last two decades because of the increased use of direct current in high voltage electrical systems. In this context, a significant relevance has been achieved by the thermal methods, used for solid dielectrics. This paper presents a review of this non-destructive measurement system used for the measurement of space charge. The thermal pulse method, the thermal step method, and the laser intensity modulation method are described. For each configuration, the principle of operation, the thicknesses analyzed, and the spatial resolution are described, reporting also the main related applications.
Collapse
Affiliation(s)
- A Imburgia
- DEIM, University of Palermo, Palermo 90128, Italy
| | - P Romano
- DEIM, University of Palermo, Palermo 90128, Italy
| | - M Caruso
- DEIM, University of Palermo, Palermo 90128, Italy
| | - F Viola
- DEIM, University of Palermo, Palermo 90128, Italy
| | - R Miceli
- DEIM, University of Palermo, Palermo 90128, Italy
| | | | - A Madonia
- DEIM, University of Palermo, Palermo 90128, Italy
| | - G Schettino
- DEIM, University of Palermo, Palermo 90128, Italy
| |
Collapse
|
42
|
Wojnilowicz M, Tortora M, Bobay BG, Santiso E, Caruso M, Micheli L, Venanzi M, Menegatti S, Cavalieri F. A combined approach for predicting the cytotoxic effect of drug-nanoaggregates. J Mater Chem B 2016; 4:6516-6523. [PMID: 32263696 DOI: 10.1039/c6tb02105k] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
We present a combined spectroscopic and computational approach aimed to elucidate the mechanism of formation and activity of etoposide nanoaggregates upon release from dextran-etoposide conjugates. Etoposide is an anticancer drug that inhibits cell growth by blocking Topoisomerase II, the key enzyme involved in re-ligation of the DNA chains during the replication process. In silico and spectroscopic analysis indicate that released etoposide nanoaggregates have a different structure, stability, and bioactivity, which depend on the pH experienced during the release. Molecular dynamics simulation and in silico docking of etoposide dimers suggest that the aggregation phenomena inhibit etoposide bioactivity, yet without drastically preventing Topoisomerase II binding. We correlated the diminished cytotoxic activity exerted by dextran-etoposide conjugates on the A549 lung cancer cells, compared to the free drug, to the formation and stability of drug nanoaggregates.
Collapse
Affiliation(s)
- M Wojnilowicz
- Department of Chemical and Biomolecular Engineering, The University of Melbourne, Parkville, Melbourne, Victoria 3010, Australia.
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Tan EH, Banna G, Ramlau R, Ceresoli G, Camerini A, Milanowski J, Caruso M, Landreau P, Vedovato JC, Kowalski D. Final results of a phase II study of oral vinorelbine (NVBo) monotherapy in patients (pts) with advanced EGFR-positive non-small-cell lung cancer (NSCLC) after failure of EGFR-TKI in first line (NAVoTRIAL 2). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.84] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
44
|
Spoto G, De Iuliis V, Petrini M, Flati V, Di Gregorio J, Vitale D, Caruso M, Dadorante V, Ciarmoli M, Robuffo I, Martinotti S, Toniato E. Effect of low energy light irradiation by light emitting diode on U937 cells. J BIOL REG HOMEOS AG 2016; 30:997-1007. [PMID: 28078845] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Photobiomodulation (PBM) can induce a set of different biological modulators either in vitro or in vivo. Experimental evidence has highlighted the role of light effects on the mechanisms related to inflammation, apoptosis and autophagy. The goal of this project was the evaluation of PBM on U937, an established cell line of histiocytic lymphoma origin. Several aspects of modulation of proinflammatory pathways were analyzed and autophagic and proapoptotic mechanisms related to low laser light exposure of cells were studied. As a source of low energy light emission, we used an NIR-LED device, characterized by an 880 nm-wavelength as light source. Flow cytometry analysis was performed on supernatants of controls and treated U937 cells to detect inflammatory cytokine levels. In order to evaluate NF-kB and caspase3 expressions, Western blot analysis was performed according to standard procedures. In this report, we show the effect of PBM on a monocyte/macrophage established tumor cell line (U-937). We demonstrate that LED exposure, in the presence or absence of lipopolysaccharide (LPS), activates cell degranulation, increased expression of Interleukin-8 (IL-8) and modulation of beta galactosidase activity. Evidence shows that the well-known pro-inflammatory nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and the apoptotic marker (caspase3/cleaved-caspase3 ratio) are up-regulated in response to a proinflammatory biochemical pathway.
Collapse
Affiliation(s)
- G Spoto
- Department of Medical, Oral and Biotechnological Sciences, University G. dAnnunzio of Chieti, Italy
| | - V De Iuliis
- Unit of Predictive Medicine and Clinical Molecular biology, SS Annunziata University Hospital, ASL Lanciano-Vasto-Chieti, University G dAnnunzio, Chieti, Italy
| | - M Petrini
- Department of Medical, Oral and Biotechnological Sciences, University G. dAnnunzio of Chieti, Italy
| | - V Flati
- Department of Biotechnological and Applied Clinical Sciences, University of LAquila, LAquila, Italy
| | - J Di Gregorio
- Department of Biotechnological and Applied Clinical Sciences, University of LAquila, LAquila, Italy
| | - D Vitale
- Department of Medical, Oral and Biotechnological Sciences, University G. dAnnunzio of Chieti, Italy
| | - M Caruso
- Department of Medical, Oral and Biotechnological Sciences, University G. dAnnunzio of Chieti, Italy
| | - V Dadorante
- Unit of Predictive Medicine and Clinical Molecular biology, SS Annunziata University Hospital, ASL Lanciano-Vasto-Chieti, University G dAnnunzio, Chieti, Italy
| | - M Ciarmoli
- CNR, Institute of Molecular Genetics, Section of Chieti, Chieti, Italy
| | - I Robuffo
- CNR, Institute of Molecular Genetics, Section of Chieti, Chieti, Italy
| | - S Martinotti
- Unit of Predictive Medicine and Clinical Molecular biology, SS Annunziata University Hospital, ASL Lanciano-Vasto-Chieti, University G dAnnunzio, Chieti, Italy
| | - E Toniato
- Department of Medical, Oral and Biotechnological Sciences, University G. dAnnunzio of Chieti, Italy
| |
Collapse
|
45
|
De Iuliis V, Ursi S, Di Tommaso LM, Caruso M, Marino A, D'Ercole S, Caputi S, Sinjari B, Festa F, Macri M, Martinotti S, Vitullo G, Toniato E. Comparative molecular analysis of bacterial species associated with periodontal disease. J BIOL REG HOMEOS AG 2016; 30:1209-1215. [PMID: 28078876] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Periodontal disease is an inflammatory disorder affecting the supporting teeth structures, including gingiva, periodontal ligament and alveolar bone, causing loss of connective tissue, reabsorption of alveolar bone and formation of periodontal pockets. The aim of this study is to find a correlation between bacterial growth and periodontal disease. Fifty-seven patients aged between 21 and 65 years, median age 46 years, were enrolled. According to gingival pocket depth, ranging from 3 to 7 mm, patients were divided into two groups: the first (30 patients, 53%) with deep pockets ³ 5 mm and the second (27 patients, 47%) less than 5 mm. The samples taken were processed for microbiological analysis by absolute quantitative real-time Taq-Man technique. Patients affected by periodontal disease were 32 (56%) and patients with gingival bleeding were 35 (61%). This data showed that the presence, the type and the bacterial load in gingival pockets were strongly correlated with gingival depth, periodontal disease and gingival bleeding. Quantitative microbiological analysis is a key point to improve patient compliance, allowing to choose the specific antibiotic treatment. avoiding antibiotic resistance and ensuring the successful outcome of therapy for periodontal disease.
Collapse
Affiliation(s)
- V De Iuliis
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Chieti, Italy
| | - S Ursi
- SS Annunziata University Hospital, Unit of Clinical Molecular Biology and Predictive Medicine, University of Chieti, ASL Lanciano-Vasto-Chieti, Chieti, Italy
| | - L M Di Tommaso
- SS Annunziata University Hospital, Unit of Clinical Molecular Biology and Predictive Medicine, University of Chieti, ASL Lanciano-Vasto-Chieti, Chieti, Italy
| | - M Caruso
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Chieti, Italy
| | - A Marino
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Chieti, Italy
| | - S D'Ercole
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Chieti, Italy
| | - S Caputi
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Chieti, Italy
| | - B Sinjari
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Chieti, Italy
| | - F Festa
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Chieti, Italy
| | - M Macri
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Chieti, Italy
| | - S Martinotti
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Chieti, Italy
- SS Annunziata University Hospital, Unit of Clinical Molecular Biology and Predictive Medicine, University of Chieti, ASL Lanciano-Vasto-Chieti, Chieti, Italy
| | - G Vitullo
- SS Annunziata University Hospital, Unit of Clinical Molecular Biology and Predictive Medicine, University of Chieti, ASL Lanciano-Vasto-Chieti, Chieti, Italy
| | - E Toniato
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Chieti, Italy
| |
Collapse
|
46
|
Aiello D, Patti S, Alì M, Sanò M, Virgilio S, Taibi E, Di Leo V, Fallica G, Caruso M, Aiello R. Evaluation of quality of life in early breast cancer disease free survivors. a cross sectional survey. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw337.52] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
47
|
Caruso M, Latorre L, Santagada G, Fraccalvieri R, Miccolupo A, Sottili R, Palazzo L, Parisi A. Methicillin-resistant Staphylococcus aureus (MRSA) in sheep and goat bulk tank milk from Southern Italy. Small Rumin Res 2016. [DOI: 10.1016/j.smallrumres.2015.12.023] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
48
|
De Cesare A, Parisi A, Giacometti F, Serraino A, Piva S, Caruso M, De Santis EPL, Manfreda G. Multilocus sequence typing of Arcobacter butzleri isolates collected from dairy plants and their products, and comparison with their PFGE types. J Appl Microbiol 2015; 120:165-74. [PMID: 26481316 DOI: 10.1111/jam.12977] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2015] [Revised: 10/09/2015] [Accepted: 10/09/2015] [Indexed: 11/26/2022]
Abstract
AIMS The present study aimed to determine, by multilocus sequence type (MLST), the heterogeneity level of Arcobacter butzleri isolates and to compare MLST and pulsed-field gel electrophoresis (PFGE) in terms of discriminatory power (DI) as well as unidirectional and bi-directional concordance. METHODS AND RESULTS Arcobacter butzleri isolates (N = 133) from dairy products and environmental samples, collected from dairy plants, were characterized by MLST and PFGE with SacII and classified in 29 sequence types (STs), 47 PFGE and 62 type strains (TS). Among the 119 alleles, 19 were previously unreported and the same for all the STs but two. A significant linkage disequilibrium was detected when the complete ST data set was analysed The DIs of MLST, PFGE and their combination were 0·937, 0·953 and 0·965 respectively. The adjusted Wallace coefficients between MLST and PFGE as well as PFGE and MLST were 0·535 and 0·720 respectively; the adjusted Rand coefficient was 0·612. CONCLUSIONS The A. butzleri studied population showed recombination to some degree. PFGE showed a DI higher than MLST. Both methods presented good concordance. The TS analysis seems to show persistence of the same strain on time and possible cross-contaminations between food and environmental sites. SIGNIFICANCE AND IMPACT OF THE STUDY This study provides insights in the A. butzleri population found in raw milk, cheese, and dairy production plants. The data suggest that MLST and PFGE genotypes correlate reasonably well, although their combination results in optimal resolution.
Collapse
Affiliation(s)
- A De Cesare
- Department of Agricultural and Food Sciences, University of Bologna, Ozzano dell'Emilia, Italy
| | - A Parisi
- Istituto Zooprofilattico Sperimentale della Puglia e della Basilicata, Putignano, Italy
| | - F Giacometti
- Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell'Emilia, Italy
| | - A Serraino
- Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell'Emilia, Italy
| | - S Piva
- Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell'Emilia, Italy
| | - M Caruso
- Istituto Zooprofilattico Sperimentale della Puglia e della Basilicata, Putignano, Italy
| | - E P L De Santis
- Department of Veterinary Medicine, University of Sassari, Sassari, Italy
| | - G Manfreda
- Department of Agricultural and Food Sciences, University of Bologna, Ozzano dell'Emilia, Italy
| |
Collapse
|
49
|
Caruso M, Jarne C. Equivalent Markov processes under gauge group. Phys Rev E Stat Nonlin Soft Matter Phys 2015; 92:052132. [PMID: 26651671 DOI: 10.1103/physreve.92.052132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/02/2015] [Indexed: 06/05/2023]
Abstract
We have studied Markov processes on denumerable state space and continuous time. We found that all these processes are connected via gauge transformations. We have used this result before as a method to resolve equations, included the case in a previous work in which the sample space is time-dependent [Phys. Rev. E 90, 022125 (2014)]. We found a general solution through dilation of the state space, although the prior probability distribution of the states defined in this new space takes smaller values with respect to that in the initial problem. The gauge (local) group of dilations modifies the distribution on the dilated space to restore the original process. In this work, we show how the Markov process in general could be linked via gauge (local) transformations, and we present some illustrative examples for this result.
Collapse
Affiliation(s)
- M Caruso
- Departamento de Física Teórica y del Cosmos, Universidad de Granada, Campus de Fuentenueva, Granada (18071), Spain
| | - C Jarne
- Instituto de Física de Buenos Aires - CONICET Facultad de Ciencias Exactas y Naturales. Pabellón I Ciudad Universitaria Post Code:1428. Buenos Aires - Argentina
| |
Collapse
|
50
|
Adamo V, Ricciardi G, Franchina V, Ferraro G, Caruso M, Bronte G, Banna G, Spadaro P, Savarino A, Iacono C, Soto Parra H, Spada M, Safina V, Blasi L, Zerilli F, Prestifilippo A, Giannitto-Giorgio C, Alberio D, Cottini L, Russo A. Multicenter study of the eValuation of Eribulin (E) use in Sicily in metastatic breast cancer (MBC): A Prospective RegistrY (VESPRY trial). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv336.57] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|